Guidance for choosing SARS-CoV-2 LOINC terms
Watch our March 2020 SARS-CoV-2/ COVID-19 webinar
This page contains LOINC terms that are related to SARS coronavirus 2 (SARS-CoV-2) and COVID-19. We are providing this page as a single source for all SARS-CoV-2/COVID-19 LOINC content. Note that the contents will be updated as new terms are created and pre-released, so check back frequently for the latest contents.
This page contains both published and pre-release terms.
- Published terms have the code highlighted in blue and contain the version in which the term was first published in the Version column;
- Pre-release terms have the code highlighted in yellow, and the Version column is empty.
Some of the terms, such as the lab terms, are specific to SARS-CoV-2/COVID-19, and some, such as the telehealth document codes, are related to the current pandemic but can also be used in different contexts. These terms will help support the HHS COVID-19 Pandemic Response, Laboratory Data Reporting: CARES Act Section 18115 requirements.
All terms were created based on requests from LOINC users. We have been working closely with APHL, CDC, FDA, labs, IVD manufacturers, and other stakeholders on the codes specifically related to SARS-CoV-2/COVID-19. To obtain the current list of LOINC mappings to SARS-CoV-2 IVD assays approved for FDA EUA, you can download the LIVD file posted on the CDC website.
Exporting data
You can download the contents of this page in .csv format. If you filter the contents, only the remaining terms will be included in the download file. In order to download you must be logged in, so that we can keep track of usage and also so that we can contact you if there is an issue with the format or contents of the file that you downloaded. The contents on this page are not static and will be automatically updated when new SARS-CoV-2/COVID-19 terms are pre-released.
Important notice regarding pre-release content
Pre-release terms are those which have not yet been published in a public release. They are also available on the LOINC pre-release page. Once they are published, they will no longer be on the pre-release page, but will still be included on this page with the appropriate Version value.
If you need to include a version when you are using one of the pre-release codes, we recommend using the following: {Version of the upcoming LOINC release}-pre. For example, the June 2021 LOINC release will be release 2.70. The version of pre-release codes published between the 2.69 release in December 2020 and 2.70 is 2.70-pre.
These SARS-CoV-2/COVID-19 codes are based on the most up to date information available at the time of their creation and they have undergone the normal QA terminology process. LOINC supports their use in the unique situation that resulted in their rapid creation.
Be aware that downstream users may not be ready to handle prerelease codes until they are published in an official release.
SARS CoV 2 lab tests
VersionFirstReleased | LOINC_NUM | Long Common Name | Component | Property | Time_Aspct | System | Scale_Typ | Method_Typ | Class | ClassType | Shortname | External_Copyright_Notice | Status | VersionLastChanged |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.69 | 96122-7 | SARS-related coronavirus E gene [Presence] in Upper respiratory specimen by NAA with probe detection | SARS-related coronavirus E gene | PrThr | Pt | Respiratory system specimen.upper | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene Upper resp Ql NAA+prb | ACTIVE | 2.77 | |
2.68 | 95209-3 | SARS-CoV+SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory system specimen by Rapid immunoassay | SARS coronavirus+ |
PrThr | Pt | Respiratory System Specimen | Ord | IA.rapid | MICRO | 1 | SARS-CoV+SARS-CoV-2 Ag Resp Ql IA.rapid | ACTIVE | 2.75 | |
2.69 | 95424-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by Sequencing | SARS coronavirus 2 RNA | PrThr | Pt | Respiratory System Specimen | Ord | Sequencing | MICRO | 1 | SARS-CoV-2 RNA Resp Ql Seq | ACTIVE | 2.75 | |
2.69 | 95423-0 | Influenza virus A and B and SARS-CoV-2 (COVID-19) identified in Respiratory system specimen by NAA with probe detection | Influenza virus A & Influenza virus B & SARS coronavirus 2 identified | Prid | Pt | Respiratory System Specimen | Nom | Probe.amp.tar | MICRO | 1 | FLUABV + SARS-CoV-2 Resp NAA+probe | ACTIVE | 2.75 | |
2.69 | 95422-2 | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection | Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel | - | Pt | Respiratory System Specimen | - | Probe.amp.tar | PANEL.MICRO | 1 | FLUABV + SARS-CoV-2 Pnl Resp NAA+prb | ACTIVE | 2.75 | |
2.69 | 96123-5 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Upper respiratory specimen by NAA with probe detection | SARS coronavirus 2 RdRp gene | PrThr | Pt | Respiratory system specimen.upper | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Upper resp Ql NAA+probe | ACTIVE | 2.77 | |
2.69 | 95522-9 | SARS-CoV-2 (COVID-19) N gene [Log #/volume] (viral load) in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 N gene | LnCnc | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Resp NAA+probe-Log# | ACTIVE | 2.75 | |
2.69 | 95521-1 | SARS-CoV-2 (COVID-19) N gene [#/volume] (viral load) in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 N gene | NCnc | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene # Resp NAA+probe | ACTIVE | 2.75 | |
2.68 | 95411-5 | SARS-CoV-2 (COVID-19) neutralizing antibody [Presence] in Serum by pVNT | SARS coronavirus 2 Ab.neut | PrThr | Pt | Ser | Ord | pVNT | MICRO | 1 | SARS-CoV-2 NAb Ser Ql pVNT | ACTIVE | 2.69 | |
2.69 | 95428-9 | SARS-CoV-2 (COVID-19) IgM Ab [Titer] in Serum or Plasma by Immunofluorescence | SARS coronavirus 2 Ab.IgM | Titr | Pt | Ser/Plas | SemiQn | IF | MICRO | 1 | SARS-CoV-2 IgM Titr SerPl IF | ACTIVE | 2.75 | |
2.68 | 94758-0 | SARS-related coronavirus E gene [Presence] in Respiratory system specimen by NAA with probe detection | SARS-related coronavirus E gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.68 | 94757-2 | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by Nucleic acid amplification using CDC primer-probe set N2 | SARS coronavirus 2 N gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar.CDC primer-probe set N2 | MICRO | 1 | SARS-CoV-2 N gene Resp Ql NAA N2 | ACTIVE | 2.75 | |
2.69 | 95427-1 | SARS-CoV-2 (COVID-19) IgA Ab [Titer] in Serum or Plasma by Immunofluorescence | SARS coronavirus 2 Ab.IgA | Titr | Pt | Ser/Plas | SemiQn | IF | MICRO | 1 | SARS-CoV-2 IgA Titr SerPl IF | ACTIVE | 2.75 | |
2.68 | 94644-2 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 ORF1ab region | ThreshNum | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab Ct Resp Qn NAA+probe | ACTIVE | 2.75 | |
2.69 | 96094-8 | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 & SARS-related coronavirus RNA panel | - | Pt | Respiratory System Specimen | - | Probe.amp.tar | PANEL.MICRO | 1 | SARS-CoV-2+SARSr-CoV pnl Resp NAA+probe | ACTIVE | 2.75 | |
2.68 | 95406-5 | SARS-CoV-2 (COVID-19) RNA [Presence] in Nose by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Nose | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Nose Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94822-4 | SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by Sequencing | SARS coronavirus 2 RNA | PrThr | Pt | Saliva | Ord | Sequencing | MICRO | 1 | SARS-CoV-2 RNA Sal Ql Seq | ACTIVE | 2.69 | |
2.69 | 95425-5 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 N gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Sal Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94769-7 | SARS-CoV-2 (COVID-19) Ab [Units/volume] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab | ACnc | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 Ab SerPl IA-aCnc | ACTIVE | 2.71 | |
2.68 | 94768-9 | SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | SARS coronavirus 2 Ab.IgA | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 IgA SerPlBld Ql IA.rapid | ACTIVE | 2.69 | |
2.68 | 94767-1 | SARS-CoV-2 (COVID-19) S gene [Presence] in Serum or Plasma by NAA with probe detection | SARS coronavirus 2 S gene | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene SerPl Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94762-2 | SARS-CoV-2 (COVID-19) Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab | PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 Ab SerPl Ql IA | ACTIVE | 2.69 | |
2.68 | 94761-4 | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in DBS by Immunoassay | SARS coronavirus 2 Ab.IgG | PrThr | Pt | Bld.dot | Ord | IA | MICRO | 1 | SARS-CoV-2 IgG DBS Ql IA | ACTIVE | 2.69 | |
2.68 | 94760-6 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nasopharynx by NAA with probe detection | SARS coronavirus 2 N gene | PrThr | Pt | Nph | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Nph Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94759-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Nph | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Nph Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94746-5 | SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Specimen by NAA with probe detection | SARS coronavirus 2 RNA | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Ct Spec Qn NAA+probe | ACTIVE | 2.69 | |
2.68 | 94745-7 | SARS-CoV-2 (COVID-19) RNA [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 RNA | ThreshNum | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Ct Resp Qn NAA+probe | ACTIVE | 2.75 | |
2.68 | 94660-8 | SARS-CoV-2 (COVID-19) RNA [Presence] in Serum or Plasma by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA SerPl Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94647-5 | SARS-related coronavirus RNA [Presence] in Specimen by NAA with probe detection | SARS-related coronavirus RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARSr-CoV RNA Spec Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94641-8 | SARS-CoV-2 (COVID-19) S gene [Presence] in Specimen by NAA with probe detection | SARS coronavirus 2 S gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene Spec Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94563-4 | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgG | PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 IgG SerPl Ql IA | ACTIVE | 2.73 | |
2.69 | 95942-9 | Influenza virus A and B and SARS-CoV+SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay | Influenza virus A & Influenza virus B & SARS coronavirus+ |
- | Pt | Respiratory system specimen.upper | - | IA.rapid | PANEL.MICRO | 1 | FLUABV+SARS-CoV Ag Pnl Up resp IA.rapid | ACTIVE | 2.77 | |
2.73 | 100345-8 | Influenza virus A and B and SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection | Influenza virus A & Influenza virus B & SARS coronavirus 2 RNA panel | - | Pt | XXX | - | Probe.amp.tar | PANEL.MICRO | 1 | FLUABV+SARS-CoV-2 RNA Pnl Spec NAA+probe | ACTIVE | 2.73 | |
2.69 | 96121-9 | SARS-related coronavirus E gene [Presence] in Lower respiratory specimen by NAA with probe detection | SARS-related coronavirus E gene | PrThr | Pt | Respiratory system specimen.lower | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene Low resp Ql NAA+prb | ACTIVE | 2.77 | |
2.69 | 96120-1 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Lower respiratory specimen by NAA with probe detection | SARS coronavirus 2 RdRp gene | PrThr | Pt | Respiratory system specimen.lower | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Lower resp Ql NAA+probe | ACTIVE | 2.77 | |
2.69 | 95608-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with non-probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Respiratory System Specimen | Ord | Non-probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Resp Ql NAA+non-probe | ACTIVE | 2.75 | |
2.68 | 95125-1 | SARS-CoV-2 (COVID-19) IgA+IgM [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgA+ |
PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 IgA+IgM SerPl Ql IA | ACTIVE | 2.69 | |
2.69 | 96448-6 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N1 | SARS coronavirus 2 N gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar.CDC primer-probe set N1 | MICRO | 1 | SARS-CoV-2 N gene Sal Ql NAA N1 | ACTIVE | 2.69 | |
2.69 | 96603-6 | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Presence] in Serum or Plasma by sVNT | SARS coronavirus 2 spike protein RBD Ab.neut | PrThr | Pt | Ser/Plas | Ord | sVNT | MICRO | 1 | SARS-CoV-2 S RBD NAb SerPl Ql sVNT | ACTIVE | 2.72 | |
2.69 | 95380-2 | Influenza virus A and B and SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Respiratory system specimen by NAA with probe detection | Influenza virus A & Influenza virus B & SARS coronavirus 2 & SARS-related coronavirus RNA panel | - | Pt | Respiratory System Specimen | - | Probe.amp.tar | PANEL.MICRO | 1 | FluAB+SARS-CoV-2+SARSr-CoV Resp NAA+prb | ACTIVE | 2.75 | |
2.68 | 94766-3 | SARS-CoV-2 (COVID-19) N gene [Presence] in Serum or Plasma by NAA with probe detection | SARS coronavirus 2 N gene | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene SerPl Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94765-5 | SARS-related coronavirus E gene [Presence] in Serum or Plasma by NAA with probe detection | SARS-related coronavirus E gene | PrThr | Pt | Ser/Plas | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene SerPl Ql NAA+probe | ACTIVE | 2.68 | |
2.68 | 94764-8 | SARS-CoV-2 (COVID-19) whole genome [Nucleotide sequence] in Isolate or Specimen by Sequencing | SARS coronavirus 2 whole genome | Seq | Pt | Isolate/Specimen | Nom | Sequencing | MICRO | 1 | SARS-CoV-2 genome Islt/Spm-Seq | ACTIVE | 2.69 | |
2.68 | 94763-0 | SARS-CoV-2 (COVID-19) [Presence] in Specimen by Organism specific culture | SARS coronavirus 2 | PrThr | Pt | XXX | Ord | Organism specific culture | MICRO | 1 | SARS-CoV-2 Spec Ql Cult | ACTIVE | 2.69 | |
2.68 | 94756-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by Nucleic acid amplification using CDC primer-probe set N1 | SARS coronavirus 2 N gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar.CDC primer-probe set N1 | MICRO | 1 | SARS-CoV-2 N gene Resp Ql NAA N1 | ACTIVE | 2.75 | |
2.68 | 94720-0 | SARS-CoV-2 (COVID-19) IgA Ab [Units/volume] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgA | ACnc | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 IgA SerPl IA-aCnc | ACTIVE | 2.69 | |
2.68 | 94661-6 | SARS-CoV-2 (COVID-19) Ab [Interpretation] in Serum or Plasma | SARS coronavirus 2 Ab | Imp | Pt | Ser/Plas | Nom | MICRO | 1 | SARS-CoV-2 Ab SerPl-Imp | ACTIVE | 2.69 | ||
2.72 | 100157-7 | SARS-CoV-2 (COVID-19) lineage [Type] in Specimen by Sequencing | SARS coronavirus 2 lineage | Type | Pt | XXX | Nom | Sequencing | MICRO | 1 | SARS-CoV-2 lineage Spec Seq | ACTIVE | 2.72 | |
2.68 | 94646-7 | SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 RdRp gene | ThreshNum | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Ct Resp Qn NAA+probe | ACTIVE | 2.75 | |
2.68 | 94645-9 | SARS-CoV-2 (COVID-19) RdRp gene [Cycle Threshold #] in Specimen by NAA with probe detection | SARS coronavirus 2 RdRp gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Ct Spec Qn NAA+probe | ACTIVE | 2.69 | |
2.68 | 94643-4 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Specimen by NAA with probe detection | SARS coronavirus 2 S gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene Ct Spec Qn NAA+probe | ACTIVE | 2.69 | |
2.68 | 94642-6 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 S gene | ThreshNum | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene Ct Resp Qn NAA+probe | ACTIVE | 2.75 | |
2.68 | 94639-2 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Specimen by NAA with probe detection | SARS coronavirus 2 ORF1ab region | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab Spec Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94559-2 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 ORF1ab region | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab Resp Ql NAA+probe | ACTIVE | 2.78 | |
2.68 | 94533-7 | SARS-CoV-2 (COVID-19) N gene [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 N gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.68 | 94510-5 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by NAA with probe detection | SARS coronavirus 2 N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Ct Spec Qn NAA+probe | ACTIVE | 2.69 | |
2.68 | 94509-7 | SARS-related coronavirus E gene [Cycle Threshold #] in Specimen by NAA with probe detection | SARS-related coronavirus E gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene Ct Spec Qn NAA+probe | ACTIVE | 2.69 | |
2.68 | 94504-8 | SARS-CoV-2 (COVID-19) Ab panel - Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab panel | - | Pt | Ser/Plas | - | IA | PANEL.MICRO | 1 | SARS-CoV-2 Ab Pnl SerPl IA | ACTIVE | 2.69 | |
2.68 | 94503-0 | SARS-CoV-2 (COVID-19) Ab panel - Serum, Plasma or Blood by Rapid immunoassay | SARS coronavirus 2 Ab panel | - | Pt | Ser/Plas/Bld | - | IA.rapid | PANEL.MICRO | 1 | SARS-CoV-2 Ab Pnl SerPlBld IA.rapid | ACTIVE | 2.69 | |
2.68 | 94502-2 | SARS-related coronavirus RNA [Presence] in Respiratory system specimen by NAA with probe detection | SARS-related coronavirus RNA | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV RNA Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.68 | 94500-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.68 | 94308-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 | SARS coronavirus 2 N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar.CDC primer-probe set N2 | MICRO | 1 | SARS-CoV-2 N gene Spec Ql NAA N2 | ACTIVE | 2.69 | |
2.68 | 94307-6 | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 | SARS coronavirus 2 N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar.CDC primer-probe set N1 | MICRO | 1 | SARS-CoV-2 N gene Spec Ql NAA N1 | ACTIVE | 2.69 | |
2.77 | 103557-5 | SARS-CoV-2 (COVID-19) Mpro gene mutation detected [Identifier] in Specimen by Molecular genetics method Nominal | SARS coronavirus 2 Mpro gene mutation detected | Prid | Pt | XXX | Nom | Molgen | MOLPATH.MUT | 1 | SARS-CoV-2 Mpro gene mut Spec | ACTIVE | 2.77 | |
2.69 | 95974-2 | SARS-CoV-2 stimulated gamma interferon panel - Blood | SARS coronavirus 2 stimulated gamma interferon panel | - | Pt | Bld | - | PANEL.MICRO | 1 | SARS-CoV-2 IFN-g Pnl Bld | ACTIVE | 2.70 | ||
2.69 | 95973-4 | SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] in Blood | SARS coronavirus 2 stimulated gamma interferon release by T-cells | ACnc | Pt | Bld | Qn | MICRO | 1 | SARS-CoV-2 IFN-g T cells Bld-aCnc | ACTIVE | 2.70 | ||
2.73 | 100342-5 | Volatile Organic Compounds associated with SARS-CoV-2 infection [Presence] in Exhaled gas by Gas chromatography-mass spectrometry | Volatile Organic Compounds associated with SARS-CoV-2 infection | PrThr | Pt | Exhl gas | Ord | GC-MS | MICRO | 1 | VOCs (volatiles) SARS-CoV-2 ExG Ql GC-MS | ACTIVE | 2.73 | |
2.68 | 95410-7 | SARS-CoV-2 (COVID-19) neutralizing antibody [Titer] in Serum by pVNT | SARS coronavirus 2 Ab.neut | Titr | Pt | Ser | SemiQn | pVNT | MICRO | 1 | SARS-CoV-2 NAb Titr Ser pVNT | ACTIVE | 2.75 | |
2.68 | 95409-9 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with probe detection | SARS coronavirus 2 N gene | PrThr | Pt | Nose | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Nose Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94819-0 | SARS-CoV-2 (COVID-19) RNA [Log #/volume] (viral load) in Specimen by NAA with probe detection | SARS coronavirus 2 RNA | LnCnc | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Spec NAA+probe-Log# | ACTIVE | 2.69 | |
2.72 | 100156-9 | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by NAA with probe detection | SARS coronavirus 2 variant | Type | Pt | XXX | Nom | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 variant Spec NAA+probe | ACTIVE | 2.72 | |
2.68 | 95416-4 | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in DBS by Immunoassay | SARS coronavirus 2 Ab.IgM | PrThr | Pt | Bld.dot | Ord | IA | MICRO | 1 | SARS-CoV-2 IgM DBS Ql IA | ACTIVE | 2.69 | |
2.69 | 95429-7 | SARS-CoV-2 (COVID-19) IgG Ab [Titer] in Serum or Plasma by Immunofluorescence | SARS coronavirus 2 Ab.IgG | Titr | Pt | Ser/Plas | SemiQn | IF | MICRO | 1 | SARS-CoV-2 IgG Titr SerPl IF | ACTIVE | 2.75 | |
2.68 | 94565-9 | SARS-CoV-2 (COVID-19) RNA [Presence] in Nasopharynx by NAA with non-probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Nph | Ord | Non-probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Nph Ql NAA+non-probe | ACTIVE | 2.73 | |
2.68 | 94547-7 | SARS-CoV-2 (COVID-19) IgG+IgM Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgG+ |
PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 IgG+IgM SerPl Ql IA | ACTIVE | 2.69 | |
2.68 | 94532-9 | SARS-related coronavirus+MERS coronavirus RNA [Presence] in Respiratory system specimen by NAA with probe detection | SARS-related coronavirus+ |
PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV+MERS RNA Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.69 | 95941-1 | Influenza virus A and B and SARS-CoV-2 (COVID-19) and Respiratory syncytial virus RNA panel - Respiratory system specimen by NAA with probe detection | Influenza virus A & Influenza virus B & SARS coronavirus 2 & Respiratory syncytial virus RNA panel | - | Pt | Respiratory System Specimen | - | Probe.amp.tar | PANEL.MICRO | 1 | FLUABV+SARS-CoV-2+RSV Pnl Resp NAA+probe | ACTIVE | 2.77 | |
2.69 | 96119-3 | SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay | SARS coronavirus 2 Ag | PrThr | Pt | Respiratory system specimen.upper | Ord | IA | MICRO | 1 | SARS-CoV-2 Ag Upper resp Ql IA | ACTIVE | 2.77 | |
2.69 | 96118-5 | SARS-CoV-2 (COVID-19) Ab panel - DBS by Immunoassay | SARS coronavirus 2 Ab panel | - | Pt | Bld.dot | - | IA | PANEL.MICRO | 1 | SARS-CoV-2 Ab Pnl DBS IA | ACTIVE | 2.69 | |
2.69 | 95542-7 | SARS-CoV-2 (COVID-19) Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | SARS coronavirus 2 Ab | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 Ab SerPlBld Ql IA.rapid | ACTIVE | 2.70 | |
2.70 | 98062-3 | Sequencing study identifier | Sequencing study identifier | ID | Pt | Specimen | Nom | MICRO | 1 | Sequencing study ID | ACTIVE | 2.72 | ||
2.68 | 94316-7 | SARS-CoV-2 (COVID-19) N gene [Presence] in Specimen by NAA with probe detection | SARS coronavirus 2 N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Spec Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94315-9 | SARS-related coronavirus E gene [Presence] in Specimen by NAA with probe detection | SARS-related coronavirus E gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene Spec Ql NAA+probe | ACTIVE | 2.69 | |
2.69 | 96091-4 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 RdRp gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Sal Ql NAA+probe | ACTIVE | 2.69 | |
2.71 | 98131-6 | SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 ORF1b region | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1b Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.71 | 98069-8 | SARS-CoV-2 (COVID-19) Ab [Presence] in Saliva (oral fluid) by Rapid immunoassay | SARS coronavirus 2 Ab | PrThr | Pt | Saliva | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 Ab Sal Ql IA.rapid | ACTIVE | 2.72 | |
2.68 | 94640-0 | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 S gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.68 | 94562-6 | SARS-CoV-2 (COVID-19) IgA Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgA | PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 IgA SerPl Ql IA | ACTIVE | 2.69 | |
2.68 | 94534-5 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 RdRp gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.68 | 94531-1 | SARS-CoV-2 (COVID-19) RNA panel - Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 RNA panel | - | Pt | Respiratory System Specimen | - | Probe.amp.tar | PANEL.MICRO | 1 | SARS-CoV-2 RNA Pnl Resp NAA+probe | ACTIVE | 2.76 | |
2.68 | 94508-9 | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | SARS coronavirus 2 Ab.IgM | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 IgM SerPlBld Ql IA.rapid | ACTIVE | 2.69 | |
2.68 | 94507-1 | SARS-CoV-2 (COVID-19) IgG Ab [Presence] in Serum, Plasma or Blood by Rapid immunoassay | SARS coronavirus 2 Ab.IgG | PrThr | Pt | Ser/Plas/Bld | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 IgG SerPlBld Ql IA.rapid | ACTIVE | 2.73 | |
2.68 | 94506-3 | SARS-CoV-2 (COVID-19) IgM Ab [Units/volume] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgM | ACnc | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 IgM SerPl IA-aCnc | ACTIVE | 2.69 | |
2.68 | 94505-5 | SARS-CoV-2 (COVID-19) IgG Ab [Units/volume] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgG | ACnc | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 IgG SerPl IA-aCnc | ACTIVE | 2.73 | |
2.68 | 94312-6 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N2 | SARS coronavirus 2 N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar.CDC primer-probe set N2 | MICRO | 1 | SARS-CoV-2 N gene Ct Spec Qn NAA N2 | ACTIVE | 2.69 | |
2.68 | 94311-8 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N1 | SARS coronavirus 2 N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar.CDC primer-probe set N1 | MICRO | 1 | SARS-CoV-2 N gene Ct Spec Qn NAA N1 | ACTIVE | 2.69 | |
2.69 | 95972-6 | SARS-CoV-2 stimulated gamma interferon release by T-cells [Units/volume] corrected for background in Blood | SARS coronavirus 2 stimulated gamma interferon release by T-cells^^corrected for background | ACnc | Pt | Bld | Qn | MICRO | 1 | SARS CoV-2 IFN-g Tcel bkgrd cor Bld-aCnc | ACTIVE | 2.72 | ||
2.69 | 95971-8 | SARS-CoV-2 stimulated gamma interferon [Presence] in Blood | SARS coronavirus 2 stimulated gamma interferon | PrThr | Pt | Bld | Ord | MICRO | 1 | SARS-CoV-2 IFN-g Bld Ql | ACTIVE | 2.70 | ||
2.69 | 95970-0 | SARS-CoV-2 (COVID-19) specific TCRB gene rearrangements [Presence] in Blood by Sequencing | SARS coronavirus 2 specific TCRB gene rearrangements | PrThr | Pt | Bld | Ord | Sequencing | MICRO | 1 | SARS-CoV-2 TCRB Bld Ql Seq | ACTIVE | 2.69 | |
2.69 | 95824-9 | SARS-CoV-2 (COVID-19) ORF1ab region [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 ORF1ab region | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab Sal Ql NAA+probe | ACTIVE | 2.69 | |
2.69 | 95823-1 | SARS-related coronavirus E gene [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS-related coronavirus E gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-rel CoV E gene Sal Ql NAA+probe | ACTIVE | 2.69 | |
2.71 | 98080-5 | SARS-CoV-2 (COVID-19) and SARS-related CoV RNA panel - Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 & SARS-related coronavirus RNA panel | - | Pt | Saliva | - | Probe.amp.tar | PANEL.MICRO | 1 | SARS-CoV-2+SARSr-CoV RNA pnl Sal NAA+prb | ACTIVE | 2.71 | |
2.68 | 94314-2 | SARS-CoV-2 (COVID-19) RdRp gene [Presence] in Specimen by NAA with probe detection | SARS coronavirus 2 RdRp gene | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RdRp Spec Ql NAA+probe | ACTIVE | 2.69 | |
2.68 | 94313-4 | SARS-related coronavirus N gene [Cycle Threshold #] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 | SARS-related coronavirus N gene | ThreshNum | Pt | XXX | Qn | Probe.amp.tar.CDC primer-probe set N3 | MICRO | 1 | SARS-related CoV N Ct Spec Qn NAA N3 | ACTIVE | 2.70 | |
2.69 | 95825-6 | SARS-CoV-2 (COVID-19) Ab [Presence] in DBS by Immunoassay | SARS coronavirus 2 Ab | PrThr | Pt | Bld.dot | Ord | IA | MICRO | 1 | SARS-CoV-2 Ab DBS Ql IA | ACTIVE | 2.69 | |
2.73 | 100858-0 | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | Cells.CD4+ |
NFr | Pt | Bld | Qn | MICRO | 1 | CD4+154/CD4 stim COVID Spike | TRIAL | 2.73 | ||
2.73 | 100859-8 | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide | NFr | Pt | Bld | Qn | MICRO | 1 | CD4 IFNg/CD4 p Stim COVID Sp | TRIAL | 2.73 | ||
2.69 | 95826-4 | SARS-CoV-2 (COVID-19) RNA panel - Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 RNA panel | - | Pt | Saliva | - | Probe.amp.tar | PANEL.MICRO | 1 | SARS-CoV-2 RNA Pnl Sal NAA+probe | ACTIVE | 2.70 | |
2.73 | 100860-6 | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Spike peptide | Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Spike peptide | NFr | Pt | Bld | Qn | MICRO | 1 | CD4 TNFa/CD4 p Stim COVID Sp | TRIAL | 2.73 | ||
2.73 | 100861-4 | Cells.CD4+CD154+/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | Cells.CD4+ |
NFr | Pt | Bld | Qn | MICRO | 1 | CD4+154/CD4 p COVID NuclCap | TRIAL | 2.73 | ||
2.73 | 100862-2 | Cells.CD4.Interferon gamma-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | Cells.CD4.Interferon gamma-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide | NFr | Pt | Bld | Qn | MICRO | 1 | CD4 IFNg/CD4 p COVID NuclCap | TRIAL | 2.73 | ||
2.73 | 100863-0 | Cells.CD4.Tumor necrosis factor alfa-expressing/CD4 cells in Blood --after stimulation with SARS-CoV-2 Nucleocapsid peptide | Cells.CD4.Tumor necrosis factor alfa-expressing/Cells.CD4^after stimulation with SARS-CoV-2 Nucleocapsid peptide | NFr | Pt | Bld | Qn | MICRO | 1 | CD4 TNFa/CD4 p COVID NuclCap | TRIAL | 2.73 | ||
2.68 | 94511-3 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Specimen by NAA with probe detection | SARS coronavirus 2 ORF1ab region | ThreshNum | Pt | XXX | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab Ct Spec Qn NAA+probe | ACTIVE | 2.69 | |
2.69 | 95609-4 | SARS-CoV-2 (COVID-19) S gene [Presence] in Respiratory system specimen by Sequencing | SARS coronavirus 2 S gene | PrThr | Pt | Respiratory System Specimen | Ord | Sequencing | MICRO | 1 | SARS-CoV-2 S gene Resp Ql Seq | ACTIVE | 2.75 | |
2.70 | 97099-6 | Influenza virus A and B and SARS-CoV-2 (COVID-19) Ag panel - Upper respiratory specimen by Rapid immunoassay | Influenza virus A & Influenza virus B & SARS coronavirus 2 Ag panel | - | Pt | Respiratory system specimen.upper | - | IA.rapid | PANEL.MICRO | 1 | FLUABV+SARS-CoV2 Ag Pnl Up resp IA.rapid | ACTIVE | 2.77 | |
2.70 | 96829-7 | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen from Donor by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | XXX^Donor | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Spec Donr Ql NAA+probe | ACTIVE | 2.70 | |
2.70 | 96763-8 | SARS-CoV-2 (COVID-19) E gene [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 E gene | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 E gene Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.70 | 96764-6 | SARS-CoV-2 (COVID-19) E gene [Cycle Threshold #] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 E gene | ThreshNum | Pt | Respiratory System Specimen | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 E gene Ct Resp Qn NAA+probe | ACTIVE | 2.75 | |
2.70 | 96765-3 | SARS-CoV-2 (COVID-19) S gene [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 S gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene Sal Ql NAA+probe | ACTIVE | 2.70 | |
2.70 | 96741-4 | SARS-CoV-2 (COVID-19) variant [Type] in Specimen by Sequencing | SARS coronavirus 2 variant | Type | Pt | XXX | Nom | Sequencing | MICRO | 1 | SARS-CoV-2 variant Spec Seq | ACTIVE | 2.77 | |
2.70 | 96742-2 | SARS-CoV-2 (COVID-19) IgG Ab [Mass/volume] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgG | MCnc | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 IgG SerPl IA-mCnc | ACTIVE | 2.70 | |
2.72 | 98732-1 | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Titer] in Serum or Plasma by Immunoassay | SARS coronavirus 2 spike protein RBD Ab.neut | Titr | Pt | Ser/Plas | SemiQn | IA | MICRO | 1 | SARS-CoV-2 S RBD NAb Titr SerPl IA | ACTIVE | 2.75 | |
2.72 | 98733-9 | Percent neutralization by SARS coronavirus 2 spike protein RBD neutralizing antibody in Serum or Plasma by Immunoassay | Percent neutralization by SARS coronavirus 2 spike protein RBD Ab.neut | AFr | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 S RBD NAb SerPl IA-% | ACTIVE | 2.72 | |
2.72 | 98734-7 | SARS-CoV-2 (COVID-19) S protein RBD neutralizing antibody [Units/volume] in Serum or Plasma by Immunoassay | SARS coronavirus 2 spike protein RBD Ab.neut | ACnc | Pt | Ser/Plas | Qn | IA | MICRO | 1 | SARS-CoV-2 S RBD NAb SerPl IA-aCnc | ACTIVE | 2.72 | |
2.72 | 98846-9 | SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+) T-cells [Units/volume] corrected for background in Blood by Immunoassay | SARS coronavirus 2 stimulated gamma interferon release by Helper (CD4+ |
ACnc | Pt | Bld | Qn | IA | MICRO | 1 | SARS-CoV-2 IFN-g CD4 cells Bld IA | ACTIVE | 2.72 | |
2.72 | 98847-7 | SARS coronavirus 2 stimulated gamma interferon release by lymphocytes [Units/volume] corrected for background in Blood by Immunoassay | SARS coronavirus 2 stimulated gamma interferon release by lymphocytes^^corrected for background | ACnc | Pt | Bld | Qn | IA | MICRO | 1 | SARS-CoV-2 IFN-g Lymphs Bld IA | ACTIVE | 2.72 | |
2.71 | 98132-4 | SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Respiratory system specimen by NAA with probe detection | SARS coronavirus 2 ORF1a region | PrThr | Pt | Respiratory System Specimen | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1a Resp Ql NAA+probe | ACTIVE | 2.75 | |
2.70 | 96755-4 | SARS-CoV-2 (COVID-19) variant interpretation in Specimen Narrative | SARS coronavirus 2 variant interpretation | Imp | Pt | XXX | Nar | MICRO | 1 | SARS-CoV-2 variant Imp Spec | ACTIVE | 2.70 | ||
2.68 | 94558-4 | SARS-CoV-2 (COVID-19) Ag [Presence] in Respiratory system specimen by Rapid immunoassay | SARS coronavirus 2 Ag | PrThr | Pt | Respiratory System Specimen | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 Ag Resp Ql IA.rapid | ACTIVE | 2.75 | |
2.68 | 94310-0 | SARS-related coronavirus N gene [Presence] in Specimen by Nucleic acid amplification using CDC primer-probe set N3 | SARS-related coronavirus N gene | PrThr | Pt | XXX | Ord | Probe.amp.tar.CDC primer-probe set N3 | MICRO | 1 | SARS-related CoV N Spec Ql NAA N3 | ACTIVE | 2.70 | |
2.68 | 94309-2 | SARS-CoV-2 (COVID-19) RNA [Presence] in Specimen by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | XXX | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Spec Ql NAA+probe | ACTIVE | 2.73 | |
2.68 | 94306-8 | SARS-CoV-2 (COVID-19) RNA panel - Specimen by NAA with probe detection | SARS coronavirus 2 RNA panel | - | Pt | XXX | - | Probe.amp.tar | PANEL.MICRO | 1 | SARS-CoV-2 RNA Pnl Spec NAA+probe | ACTIVE | 2.69 | |
2.70 | 96894-1 | SARS-CoV-2 (COVID-19) sequencing and identification panel - Specimen by Molecular genetics method | SARS coronavirus 2 sequencing & identification panel | - | Pt | XXX | - | Molgen | PANEL.MICRO | 1 | SARS-CoV-2 Seq and ID Pnl Spec | ACTIVE | 2.70 | |
2.70 | 96895-8 | SARS-CoV-2 (COVID-19) lineage [Identifier] in Specimen by Molecular genetics method | SARS coronavirus 2 lineage | Prid | Pt | XXX | Nom | Molgen | MICRO | 1 | SARS-CoV-2 lineage Spec | ACTIVE | 2.72 | |
2.70 | 96896-6 | SARS-CoV-2 (COVID-19) clade [Type] in Specimen by Molecular genetics method | SARS coronavirus 2 clade | Type | Pt | XXX | Nom | Molgen | MICRO | 1 | SARS-CoV-2 clade Spec | ACTIVE | 2.72 | |
2.68 | 94845-5 | SARS-CoV-2 (COVID-19) RNA [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA Sal Ql NAA+probe | ACTIVE | 2.69 | |
2.70 | 96897-4 | SARS-CoV-2 (COVID-19) RNA panel - Oropharyngeal wash by NAA with probe detection | SARS coronavirus 2 RNA panel | - | Pt | Oropharyngeal wash | - | Probe.amp.tar | PANEL.MICRO | 1 | SARS-CoV-2 RNA Pnl OPA wash NAA+probe | ACTIVE | 2.70 | |
2.70 | 96898-2 | SARS-CoV-2 (COVID-19) N gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | SARS coronavirus 2 N gene | ThreshNum | Pt | Oropharyngeal wash | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Ct OPA wash Qn NAA+prb | ACTIVE | 2.70 | |
2.70 | 96899-0 | SARS-CoV-2 (COVID-19) ORF1ab region [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | SARS coronavirus 2 ORF1ab region | ThreshNum | Pt | Oropharyngeal wash | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab Ct OPA wash Qn NAA+prb | ACTIVE | 2.70 | |
2.70 | 96900-6 | SARS-CoV-2 (COVID-19) S gene [Cycle Threshold #] in Oropharyngeal wash by NAA with probe detection | SARS coronavirus 2 S gene | ThreshNum | Pt | Oropharyngeal wash | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 S gene Ct OPA wash Qn NAA+prb | ACTIVE | 2.70 | |
2.70 | 96986-5 | SARS-CoV-2 (COVID-19) N gene [Presence] in Nose by NAA with non-probe detection | SARS coronavirus 2 N gene | PrThr | Pt | Nose | Ord | Non-probe.amp.tar | MICRO | 1 | SARS-CoV-2 N gene Nose Ql NAA+non-probe | ACTIVE | 2.70 | |
2.70 | 96958-4 | SARS-CoV-2 (COVID-19) N gene [Presence] in Saliva (oral fluid) by Nucleic acid amplification using CDC primer-probe set N2 | SARS coronavirus 2 N gene | PrThr | Pt | Saliva | Ord | Probe.amp.tar.CDC primer-probe set N2 | MICRO | 1 | SARS-CoV-2 N gene Sal Ql NAA N2 | ACTIVE | 2.70 | |
2.70 | 97097-0 | SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay | SARS coronavirus 2 Ag | PrThr | Pt | Respiratory system specimen.upper | Ord | IA.rapid | MICRO | 1 | SARS-CoV-2 Ag Upper resp Ql IA.rapid | ACTIVE | 2.77 | |
2.70 | 97098-8 | SARS-CoV-2 (COVID-19) Nsp2 gene [Presence] in Upper respiratory specimen by NAA with probe detection | SARS coronavirus 2 Nsp2 gene | PrThr | Pt | Respiratory system specimen.upper | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 Nsp2 Upper resp Ql NAA+probe | ACTIVE | 2.77 | |
2.70 | 96751-3 | SARS-CoV-2 (COVID-19) S gene mutation detected [Identifier] in Specimen by Molecular genetics method | SARS coronavirus 2 S gene mutation detected | Prid | Pt | XXX | Nom | Molgen | MICRO | 1 | SARS-CoV-2 S gene mut Spec | ACTIVE | 2.74 | |
2.70 | 96752-1 | SARS-CoV-2 (COVID-19) S gene mutation [Presence] in Specimen by Molecular genetics method | SARS coronavirus 2 S gene mutation | PrThr | Pt | XXX | Ord | Molgen | MICRO | 1 | SARS-CoV-2 S gene mut Spec Ql | ACTIVE | 2.70 | |
2.70 | 96766-1 | GISAID sequence accession number | GISAID sequence accession number | ID | Pt | Isolate | Nom | MICRO | 1 | GISAID seq accession ID | ACTIVE | 2.70 | ||
2.71 | 98493-0 | SARS-CoV-2 (COVID-19) ORF1b region [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 ORF1b region | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1b Sal Ql NAA+probe | ACTIVE | 2.72 | |
2.71 | 98494-8 | SARS-CoV-2 (COVID-19) ORF1a region [Presence] in Saliva (oral fluid) by NAA with probe detection | SARS coronavirus 2 ORF1a region | PrThr | Pt | Saliva | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1a Sal Ql NAA+probe | ACTIVE | 2.72 | |
2.72 | 99314-7 | SARS-CoV-2 (COVID-19) RdRp gene mutation detected [Identifier] in Specimen by Molecular genetics method | SARS coronavirus 2 RdRp gene mutation detected | Prid | Pt | XXX | Nom | Molgen | MICRO | 1 | SARS-CoV-2 RdRp mut Spec | ACTIVE | 2.72 | |
2.72 | 99596-9 | SARS-CoV-2 (COVID-19) N protein IgG Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 nucleocapsid protein Ab.IgG | PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 N IgG SerPl Ql IA | ACTIVE | 2.72 | |
2.72 | 99597-7 | SARS-CoV-2 (COVID-19) S protein IgG Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 spike protein Ab.IgG | PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 S IgG SerPl Ql IA | ACTIVE | 2.72 | |
2.70 | 96797-6 | SARS-CoV-2 (COVID-19) RNA [Presence] in Oropharyngeal wash by NAA with probe detection | SARS coronavirus 2 RNA | PrThr | Pt | Oropharyngeal wash | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 RNA OPA wash Ql NAA+probe | ACTIVE | 2.70 | |
2.68 | 94564-2 | SARS-CoV-2 (COVID-19) IgM Ab [Presence] in Serum or Plasma by Immunoassay | SARS coronavirus 2 Ab.IgM | PrThr | Pt | Ser/Plas | Ord | IA | MICRO | 1 | SARS-CoV-2 IgM SerPl Ql IA | ACTIVE | 2.69 | |
2.70 | 96957-6 | SARS-CoV-2 (COVID-19) M gene [Presence] in Upper respiratory specimen by NAA with probe detection | SARS coronavirus 2 M gene | PrThr | Pt | Respiratory system specimen.upper | Ord | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 M gene Upper resp Ql NAA+prb | ACTIVE | 2.77 | |
2.72 | 99771-8 | SARS coronavirus 2 spike and nucleocapsid protein stimulated gamma interferon panel - Blood | SARS coronavirus 2 spike & nucleocapsid protein stimulated gamma interferon panel | - | Pt | Bld | - | PANEL.MICRO | 1 | SARS-CoV-2 IGRA Spk+Nuclcp Pnl Bld | ACTIVE | 2.72 | ||
2.70 | 97104-4 | SARS-CoV-2 (COVID-19) ORF1ab region [Units/volume] (viral load) in Upper respiratory specimen by NAA with probe detection | SARS coronavirus 2 ORF1ab region | ACnc | Pt | Respiratory system specimen.upper | Qn | Probe.amp.tar | MICRO | 1 | SARS-CoV-2 ORF1ab U resp NAA+probe-aCnc | ACTIVE | 2.77 | |
2.72 | 99772-6 | SARS-CoV-2 stimulated gamma interferon [Interpretation] in Blood Qualitative | SARS coronavirus 2 stimulated gamma interferon | Imp | Pt | Bld | Ord | MICRO | 1 | SARS-CoV-2 IFN-g Bld-Imp | ACTIVE | 2.72 | ||
2.72 | 99773-4 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count [#] corrected for background in Blood | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Spike Ag spot count^^corrected for background | Num | Pt | Bld | Qn | MICRO | 1 | SARSCoV2 IGRA Spike Ct bckgrd cor Bld | ACTIVE | 2.72 | ||
2.72 | 99774-2 | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count [#] corrected for background in Blood | SARS coronavirus 2 stimulated gamma interferon release by T-cells.Nucleocapsid Ag spot count^^corrected for background | Num | Pt | Bld | Qn | MICRO | 1 | SARSCoV2 IGRA Nucpsid Ct bckgrd cor Bld | ACTIVE | 2.72 |
LOINC terms for SARS-CoV-2 AOE questions
VersionFirstReleased | LOINC_NUM | Long Common Name | Component | Property | Time_Aspct | System | Scale_Typ | Method_Typ | Class | ClassType | Shortname | External_Copyright_Notice | Status | VersionLastChanged |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.36 | 65222-2 | Date and time of symptom onset | Symptom onset | TmStp | Pt | ^Patient | Qn | H&P.PX | 2 | Date+time symptom onset | ACTIVE | 2.72 | ||
2.04 | 30525-0 | Age | Age | Time | Pt | ^Patient | Qn | MISC | 1 | Age | ACTIVE | 2.73 | ||
2.69 | 95417-2 | Whether this is the patient's first test for condition of interest | First test for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | First test for condition of interest | ACTIVE | 2.71 | ||
2.69 | 95418-0 | Whether patient is employed in a healthcare setting | Employed in a healthcare setting | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Employed in healthcare setting | ACTIVE | 2.69 | ||
2.69 | 95419-8 | Whether the patient has symptoms related to condition of interest | Has symptoms related to condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Has symptoms for condition | ACTIVE | 2.69 | ||
2.69 | 95420-6 | Whether the patient was admitted to intensive care unit (ICU) for condition of interest | Admitted to intensive care unit for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Admitted to ICU for condition | ACTIVE | 2.69 | ||
2.69 | 95421-4 | Whether patient resides in a congregate care setting | Resides in a congregate care setting | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Resides in a congregate care setting | ACTIVE | 2.69 | ||
2.52 | 77974-4 | Whether the patient was hospitalized for condition of interest | Hospitalized for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Hospitalized for condition | ACTIVE | 2.69 | ||
2.58 | 82810-3 | Pregnancy status | Pregnancy status | Find | Pt | ^Patient | Nom | H&P.HX | 2 | Pregnancy status | ACTIVE | 2.73 | ||
2.69 | 96553-3 | Date of subsequent report to public health department | Date of subsequent report to public health department | Date | Pt | ^Patient | Qn | PUBLICHEALTH | 2 | Subseq rpt date to PHD | ACTIVE | 2.69 | ||
2.70 | 97155-6 | SARS coronavirus 2 (COVID-19) immunization status | SARS coronavirus 2 immunization status | Hx | Pt | ^Patient | Nom | VACCIN | 2 | SARS-CoV-2 immunization status | ACTIVE | 2.70 |
Convalescent plasma
VersionFirstReleased | LOINC_NUM | Long Common Name | Component | Property | Time_Aspct | System | Scale_Typ | Method_Typ | Class | ClassType | Shortname | External_Copyright_Notice | Status | VersionLastChanged |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.68 | 95355-4 | Convalescent plasma given [Volume] | Convalescent plasma given | Vol | Pt | ^Patient | Qn | BLDBK | 1 | Convl plasma Gvn Vol | ACTIVE | 2.68 | ||
2.68 | 95354-7 | Transfuse convalescent plasma [Volume] | Transfuse convalescent plasma | Vol | Pt | ^Patient | Qn | BLDBK | 1 | Trans Convl Plasma Vol | ACTIVE | 2.68 |
LOINC terms related to public health case reporting
VersionFirstReleased | LOINC_NUM | Long Common Name | Component | Property | Time_Aspct | System | Scale_Typ | Method_Typ | Class | ClassType | Shortname | External_Copyright_Notice | Status | VersionLastChanged |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.36 | 65222-2 | Date and time of symptom onset | Symptom onset | TmStp | Pt | ^Patient | Qn | H&P.PX | 2 | Date+time symptom onset | ACTIVE | 2.72 | ||
2.68 | 94650-9 | Contact identifier Contact | Contact identifier | ID | Pt | ^Contact | Nom | ADMIN.ID | 2 | Contact ID Contact | ACTIVE | 2.68 | ||
2.68 | 94651-7 | Country of travel [Location] | Country of travel | Loc | Pt | ^Patient | Nom | H&P.HX | 2 | Country of trav | ACTIVE | 2.68 | ||
2.68 | 94652-5 | Known exposure date | Known exposure date | Date | Pt | ^Patient | Qn | H&P.HX | 2 | Exposure date | ACTIVE | 2.68 | ||
2.68 | 94653-3 | City of travel [Location] | City of travel | Loc | Pt | ^Patient | Nom | H&P.HX | 2 | City of trav | ACTIVE | 2.68 | ||
2.68 | 94654-1 | Known exposure panel | Known exposure panel | - | Pt | ^Patient | - | PANEL.H&P | 2 | Exposure pnl | ACTIVE | 2.68 | ||
2.68 | 94656-6 | State of known exposure | State of known exposure | Loc | Pt | ^Patient | Nom | H&P.HX | 2 | State of exposure | ACTIVE | 2.68 | ||
2.68 | 94657-4 | Contact case identifier | Case identifier | ID | Pt | ^Contact | Nom | ADMIN | 2 | Case ID Contact | ACTIVE | 2.68 | ||
2.68 | 94658-2 | City of known exposure | City of known exposure | Loc | Pt | ^Patient | Nom | H&P.HX | 2 | City of exposure | ACTIVE | 2.68 | ||
2.68 | 95386-9 | Date and time of most recent contact with confirmed case | Date and time of most recent contact with confirmed case | Date | Pt | ^Patient | Qn | H&P.PX | 2 | D/T most recent contact w case | ACTIVE | 2.69 | ||
2.69 | 96553-3 | Date of subsequent report to public health department | Date of subsequent report to public health department | Date | Pt | ^Patient | Qn | PUBLICHEALTH | 2 | Subseq rpt date to PHD | ACTIVE | 2.69 | ||
2.04 | 30525-0 | Age | Age | Time | Pt | ^Patient | Qn | MISC | 1 | Age | ACTIVE | 2.73 | ||
2.52 | 77974-4 | Whether the patient was hospitalized for condition of interest | Hospitalized for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Hospitalized for condition | ACTIVE | 2.69 | ||
2.58 | 82810-3 | Pregnancy status | Pregnancy status | Find | Pt | ^Patient | Nom | H&P.HX | 2 | Pregnancy status | ACTIVE | 2.73 | ||
2.68 | 94545-1 | Household contacts [#] | Household contacts | Num | Pt | ^Patient | Qn | ADMIN | 2 | Household contacts | ACTIVE | 2.68 | ||
2.68 | 94546-9 | Relationship to individual with confirmed or suspected illness | Relationship to individual with confirmed or suspected illness | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Rel to ind w conf/susp ill | ACTIVE | 2.68 | ||
2.68 | 94655-8 | Identifier and Assigning authority panel | Identifier & Assigning authority panel | - | Pt | ^Patient | - | PANEL.ADMIN | 2 | ID & Authority panel | ACTIVE | 2.68 | ||
2.68 | 94659-0 | Case identifier | Case identifier | ID | Pt | ^Patient | Nom | ADMIN | 2 | Case ID | ACTIVE | 2.68 | ||
2.68 | 95368-7 | Intensive care unit (ICU) discharge date | Intensive care unit discharge date | Date | Pt | ^Patient | Qn | H&P.HX | 2 | ICU discharge date | ACTIVE | 2.69 | ||
2.68 | 95369-5 | Affiliated with a tribe | Affiliated with a tribe | Find | Pt | ^Patient | Ord | ADMIN.DEMOG | 2 | Affiliated with tribe | ACTIVE | 2.68 | ||
2.68 | 95370-3 | Tribal affiliation | Tribal affiliation | Type | Pt | ^Patient | Nom | ADMIN.DEMOG | 2 | Tribal affiliation | ACTIVE | 2.68 | ||
2.68 | 95371-1 | Enrolled in a tribe | Enrolled in a tribe | Find | Pt | ^Patient | Ord | ADMIN.DEMOG | 2 | Enrolled tribe | ACTIVE | 2.68 | ||
2.68 | 95372-9 | Workplace setting | Workplace setting | Type | Pt | ^Patient | Nom | ADMIN.DEMOG | 2 | Workplace | ACTIVE | 2.68 | ||
2.68 | 95373-7 | Workplace is a part of critical infrastructure | Workplace is a part of critical infrastructure | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Workplace part of crit infrastructure | ACTIVE | 2.68 | ||
2.68 | 95374-5 | Critical infrastructure workplace setting | Critical infrastructure workplace setting | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Crit infrastructure workplace type | ACTIVE | 2.68 | ||
2.68 | 95375-2 | Contact was with U.S. or international case | Contact was with U.S. or international case | Find | Pt | ^Patient | Nom | H&P.HX | 2 | Contact w/U.S. case | ACTIVE | 2.68 | ||
2.68 | 95376-0 | Type of animal exposed to | Type of animal exposed to | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Type of animal exposed to | ACTIVE | 2.68 | ||
2.68 | 95377-8 | Disability type | Disability | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Disability | ACTIVE | 2.68 | ||
2.68 | 95382-8 | Date and time of symptom resolution | Date and time of symptom resolution | TmStp | Pt | ^Patient | Qn | CLIN | 2 | D/T symptom resolution | ACTIVE | 2.68 | ||
2.68 | 95383-6 | Symptom resolution status | Symptom resolution status | Find | Pt | ^Patient | Ord | CLIN | 2 | Symptom res status | ACTIVE | 2.68 | ||
2.69 | 96539-2 | Is the patient on mechanical ventilation for condition of interest | Mechanical ventilation for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Mech vent for condition | ACTIVE | 2.77 | ||
2.69 | 96540-0 | Whether the patient received ECMO for condition of interest | Extracorporeal membrane oxygenation for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | ECMO for condition | ACTIVE | 2.69 | ||
2.69 | 96541-8 | Patient is within 6 weeks postpartum | Patient is within 6 weeks postpartum | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Within 6 wks postpartum | ACTIVE | 2.69 | ||
2.69 | 96542-6 | Travel in 14 days prior to symptom onset | Travel in 14 days prior to symptom onset | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Travel 14D prior to symp | ACTIVE | 2.69 | ||
2.69 | 96543-4 | Visited healthcare facility in 14 days prior to symptom onset | Visited healthcare facility in 14 days prior to symptom onset | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Visit healthcare fac 14D prior to symp | ACTIVE | 2.69 | ||
2.69 | 96544-2 | Contact with confirmed case in 14 days prior to symptom onset | Contact with confirmed case in 14 days prior to symptom onset | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Cont w conf case 14D prior to symp | ACTIVE | 2.69 | ||
2.69 | 96551-7 | Number of contacts followed for contact tracing | Number of contacts followed for contact tracing | Num | Pt | ^Patient | Qn | PUBLICHEALTH | 2 | # contacts for contact tracing | ACTIVE | 2.69 | ||
2.69 | 96552-5 | Result of most recent lab test for condition of interest | Result of most recent lab test for condition of interest | Find | Pt | ^Patient | Nom | PUBLICHEALTH | 2 | Result latest lab test for cond of int | ACTIVE | 2.69 | ||
2.69 | 95418-0 | Whether patient is employed in a healthcare setting | Employed in a healthcare setting | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Employed in healthcare setting | ACTIVE | 2.69 | ||
2.69 | 95420-6 | Whether the patient was admitted to intensive care unit (ICU) for condition of interest | Admitted to intensive care unit for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Admitted to ICU for condition | ACTIVE | 2.69 | ||
2.52 | 77983-5 | Country of usual residence [Location] | Country of usual residence | Loc | Pt | ^Patient | Nom | ADMIN.PATIENT.DEMOG | 2 | Country of usual residence | ACTIVE | 2.66 | ||
2.52 | 77984-3 | Country of exposure to illness [Location] | Country of exposure to illness | Loc | Pt | ^Patient | Nom | H&P.HX | 2 | Country exp to illness | ACTIVE | 2.54 | ||
2.68 | 94648-3 | Date contact confirmed as a case | Date of case confirmation | Date | Pt | ^Contact | Qn | PUBLICHEALTH | 2 | Date contact confirmed as case | ACTIVE | 2.68 | ||
2.68 | 94649-1 | Health department identifier | Health department | ID | Pt | Organization | Nom | ADMIN.FACILITY | 2 | Health dept ID | ACTIVE | 2.68 | ||
2.68 | 95367-9 | Intensive care unit (ICU) admission date | Intensive care unit admission date | Date | Pt | ^Patient | Qn | H&P.HX | 2 | ICU admission date | ACTIVE | 2.69 | ||
2.68 | 95366-1 | Date of first positive specimen collection | Date of first positive specimen collection | Date | Pt | ^Patient | Qn | SPEC | 1 | Dt of 1st pos specimen collection | ACTIVE | 2.68 | ||
2.68 | 95365-3 | Criteria used for case classification | Criteria used for case classification | Find | Pt | ^Patient | Nom | PUBLICHEALTH | 2 | Criteria for case classification | ACTIVE | 2.68 | ||
2.68 | 95364-6 | Personnel Organization | Organization | ID | Pt | Personnel | Nom | ADMIN | 2 | Personnel | ACTIVE | 2.68 | ||
2.52 | 77966-0 | Reporting state | Reporting state | Loc | Pt | ^Event | Nom | SURVEY.CDC | 4 | ACTIVE | 2.70 | |||
2.68 | 94544-4 | Exposure source in 30 days prior to onset of illness | Exposure source in 30D prior to onset of illness | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Exp source 30D prior onset | ACTIVE | 2.68 | ||
2.64 | 88636-6 | Known exposure [Identifier] | Known exposure | Prid | Pt | ^Patient | Nom | H&P.HX | 2 | Known exposure | ACTIVE | 2.73 | ||
1.0h(3) | 8656-1 | Hospital admission date | Hospital admission date | TmStp | Pt | ^Patient | Qn | H&P.HX | 2 | Hospital admission date | ACTIVE | 2.27 | ||
1.0h(3) | 8649-6 | Hospital discharge date | Hospital discharge date | TmStp | Pt | ^Patient | Qn | H&P.HX | 2 | Hospital discharge date | ACTIVE | 2.27 | ||
2.58 | 82764-2 | Country of travel outside the U.S. [Location] 2 years | Country of travel outside the U.S. | Loc | 2Y | ^Patient | Nom | H&P.HX | 2 | Trav country outside U.S. 2Y | ACTIVE | 2.58 | ||
2.58 | 82754-3 | State of travel | State of travel | Loc | Pt | ^Patient | Nom | H&P.HX | 2 | St of travel | ACTIVE | 2.58 | ||
2.54 | 80398-1 | Unique identifier for Current sample | Unique identifier | ID | Pt | Current sample | Nom | SPEC | 1 | Unique ID Current sample | ACTIVE | 2.73 | ||
2.52 | 77994-2 | Date of first report to Centers for Disease Control and Prevention [CDC.PHIN] | Date of first report to Centers for Disease Control and Prevention | TmStp | Pt | ^Event | Qn | CDC.PHIN | SURVEY.CDC | 4 | ACTIVE | 2.52 | ||
2.52 | 77978-5 | Patient died from illness of interest | Patient died from illness of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Pt died from illness | ACTIVE | 2.54 | ||
2.52 | 77968-6 | National reporting jurisdiction | National reporting jurisdiction | Loc | Pt | ^Event | Nom | SURVEY.CDC | 4 | ACTIVE | 2.66 | |||
2.40 | 71740-5 | Personnel Last (Family) name | Last name | Pn | Pt | Personnel | Nom | ADMIN | 2 | Personnel Last name | ACTIVE | 2.70 | ||
2.40 | 71739-7 | Personnel First (Given) name | First name | Pn | Pt | Personnel | Nom | ADMIN | 2 | Personnel First name | ACTIVE | 2.70 | ||
2.40 | 71728-0 | Personnel Email address | Email address | EmailAddr | Pt | Personnel | Nom | ADMIN | 2 | Personnel Email address | ACTIVE | 2.66 | ||
2.40 | 71726-4 | Personnel Business phone number | Business phone number | Tele | Pt | Personnel | Nom | ADMIN | 2 | Personnel Business phone # | ACTIVE | 2.66 | ||
2.70 | 97852-8 | COVID-19 clinical status by WHO classification | COVID-19 clinical status | Find | Pt | ^Patient | Ord | WHO classification | H&P.HX | 2 | COVID-19 clinical status WHO | ACTIVE | 2.70 | |
2.71 | 98077-1 | Whether the patient previously met the case definition for condition of interest | Whether the patient previously met the case definition for condition of interest | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Previous case condition of interest | ACTIVE | 2.71 | ||
2.72 | 99500-1 | Clinical trial vaccine received | Clinical trial vaccine received | Find | Pt | ^Patient | Ord | VACCIN | 2 | Clin trial vaccine received | ACTIVE | 2.72 | ||
2.54 | 80437-7 | Employer country [Location] | Employer country | Loc | Pt | ^Patient | Nom | ADMIN.PATIENT | 2 | Employer country | ACTIVE | 2.69 | ||
2.38 | 67098-4 | Reason for test or procedure | Reason for test or procedure | Find | Pt | ^Patient | Nom | PHENX | 2 | Reason for test procedure | ACTIVE | 2.73 | ||
2.70 | 97001-2 | Vaccine administration tier | Vaccine administration tier | Type | Pt | ^Event | Nom | VACCIN | 2 | Vaccine administration tier | ACTIVE | 2.70 | ||
2.70 | 97000-4 | Vaccine doses distributed for use in long term care facilities [#] | Vaccine doses distributed for use in long term care facilities | Num | Pt | ^Event | Qn | VACCIN | 2 | Vaccine doses distributed to LTCFs | ACTIVE | 2.70 | ||
2.70 | 96999-8 | Count of people who are fully vaccinated per 100,000 population | People who are fully vaccinated/100,000 population | NFr | Pt | ^Population | Qn | VACCIN | 2 | People who fully vaccinated/100,000 pop | ACTIVE | 2.70 | ||
2.70 | 96998-0 | Count of people who are fully vaccinated in Population | People who are fully vaccinated | Num | Pt | ^Population | Qn | VACCIN | 2 | People who fully vaccinated Pop | ACTIVE | 2.70 | ||
2.70 | 96997-2 | Count of people who initiated vaccination per 100,000 population | People who have received first dose of vaccine/100,000 population | NFr | Pt | ^Population | Qn | VACCIN | 2 | Rcvd first dose of vaccine/100,00 pop | ACTIVE | 2.70 | ||
2.70 | 96996-4 | People who have received first dose of vaccine [#] Population | People who have received first dose of vaccine | Num | Pt | ^Population | Qn | VACCIN | 2 | People rcvd first dose of vaccine Pop | ACTIVE | 2.70 | ||
2.70 | 96995-6 | Total vaccine doses distributed per 100,000 population | Vaccine doses distributed/100,000 population | NRto | Pt | ^Event | Qn | VACCIN | 2 | Vac doses dist per 100,000 | ACTIVE | 2.70 | ||
2.70 | 96989-9 | Vaccine MVX code | MVX code | ID | Pt | Vaccine | Nom | VACCIN | 2 | Vaccine MVX code | ACTIVE | 2.70 | ||
2.70 | 96988-1 | Vaccine CVX code | CVX code | ID | Pt | Vaccine | Nom | VACCIN | 2 | Vaccine CVX code | ACTIVE | 2.70 | ||
2.69 | 96550-9 | Date of most recent lab test for condition of interest | Date of most recent lab test for condition of interest | Date | Pt | ^Patient | Qn | PUBLICHEALTH | 2 | Date latest lab test for cond of int | ACTIVE | 2.69 | ||
2.69 | 96549-1 | Date and time of infection control isolation | Date and time of infection control isolation | TmStp | Pt | ^Patient | Qn | PUBLICHEALTH | 2 | D/T infection cont isolation | ACTIVE | 2.69 | ||
2.69 | 96548-3 | Whether the patient was isolated per Infection Prevention and Control guidelines | Isolated per Infection Prevention and Control guidelines | Find | Pt | ^Patient | Ord | PUBLICHEALTH | 2 | Isolated per IPC guidelines | ACTIVE | 2.69 | ||
2.69 | 96547-5 | Province, state, or region where diagnosed | Province, state, or region where diagnosed | Loc | Pt | ^Patient | Nom | PUBLICHEALTH | 2 | Province, state or region where dx | ACTIVE | 2.69 | ||
2.69 | 96546-7 | Country where diagnosed | Country where diagnosed | Loc | Pt | ^Patient | Nom | PUBLICHEALTH | 2 | Country where dx | ACTIVE | 2.69 | ||
2.69 | 96545-9 | Date and time of first contact with confirmed case | Date and time of first contact with confirmed case | TmStp | Pt | ^Patient | Qn | H&P.HX | 2 | D/T first contact w case | ACTIVE | 2.69 | ||
2.52 | 77998-3 | Age at time of case investigation | Age at time of case investigation | Time | Pt | ^Patient | Qn | SURVEY.CDC | 4 | ACTIVE | 2.52 | |||
2.52 | 77996-7 | Pregnancy status at time of illness or condition | Pregnancy status at time of illness or condition | Find | Pt | ^Patient | Ord | H&P.HX | 2 | Preg stat at illness cond | ACTIVE | 2.52 | ||
2.52 | 77990-0 | Case class status [CDC.PHIN] | Case class status | Type | Pt | ^Event | Nom | CDC.PHIN | SURVEY.CDC | 4 | ACTIVE | 2.52 | ||
2.52 | 77999-1 | Case notification comment | Case notification comment | Imp | Pt | ^Event | Nom | SURVEY.CDC | 4 | ACTIVE | 2.52 | |||
2.52 | 77997-5 | Legacy case identifier [CDC.PHIN] | Legacy case identifier | ID | Pt | ^Event | Nom | CDC.PHIN | SURVEY.CDC | 4 | ACTIVE | 2.52 | ||
2.50 | 75617-1 | Residence [NAMCS] | Residence | Type | Pt | ^Patient | Nom | NAMCS | SURVEY.NHCS | 4 | ACTIVE | 2.73 | ||
2.38 | 66455-7 | Condition status | Condition status | Find | Pt | ^Patient | Nom | H&P.HX | 2 | Condition status | ACTIVE | 2.72 | ||
2.29 | 56831-1 | Problem associated signs and symptoms | Problem associated signs and symptoms | Find | Pt | ^Patient | Nom | ED | 2 | Problem associated signs+symptoms | ACTIVE | 2.73 | ||
2.50 | 75618-9 | Comorbid condition | Comorbid condition | Find | Pt | ^Patient | Nom | H&P.HX | 2 | Comorbid condition | ACTIVE | 2.70 | ||
2.66 | 91560-3 | Date of departure from travel destination | Date of departure from travel destination | Date | Pt | ^Patient | Qn | H&P.HX | 2 | Date of departure from destination | ACTIVE | 2.66 | ||
2.52 | 76696-4 | Name [Identifier] Facility | Name | ID | Pt | Facility | Nom | ADMIN.FACILITY | 2 | Name Facility | ACTIVE | 2.66 | ||
2.07 | 31208-2 | Specimen source identified | Specimen | Source | Pt | XXX | Nom | SPEC | 1 | Specimen source | ACTIVE | 2.79 | ||
2.52 | 76689-9 | Sex assigned at birth | Sex assigned^at birth | Type | Pt | ^Patient | Nom | ADMIN.PATIENT.DEMOG | 2 | Sex assigned at birth | ACTIVE | 2.71 | ||
2.70 | 96994-9 | Vaccine doses distributed [#] | Vaccine doses distributed | Num | Pt | ^Event | Qn | VACCIN | 2 | Vaccine doses distributed | ACTIVE | 2.70 | ||
2.70 | 96992-3 | State where vaccine was administered | Vaccine administration state | Loc | Pt | ^Event | Nom | VACCIN | 2 | Vaccine administration state | ACTIVE | 2.70 | ||
2.70 | 96991-5 | Vaccine administration county [Location] | Vaccine administration county | Loc | Pt | ^Event | Nom | VACCIN | 2 | Vaccine administration county | ACTIVE | 2.70 | ||
2.70 | 96990-7 | Vaccine administration location | Vaccine administration location | Type | Pt | ^Event | Nom | VACCIN | 2 | Vaccine administration loc | ACTIVE | 2.70 | ||
2.68 | 95041-0 | COVID-19 Progress note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Progress note | ACTIVE | 2.70 | |
2.54 | 80431-0 | Employer city | Employer city | Loc | Pt | ^Patient | Nom | ADMIN.PATIENT | 2 | Employer city | ACTIVE | 2.69 | ||
2.56 | 81267-7 | Setting of exposure to illness | Setting of exposure to illness | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Setting of exposure to illness | ACTIVE | 2.56 | ||
2.66 | 91541-3 | Disease outcome [Type] | Disease outcome | Type | Pt | ^Patient | Nom | H&P.HX | 2 | Disease outcome Type | ACTIVE | 2.68 | ||
2.48 | 74549-7 | Reporter of adverse event or unsafe condition | Reporter of adverse event or unsafe condition | Pn | Pt | ^Event | Nom | SURVEY.AHRQ | 4 | ACTIVE | 2.48 | |||
2.48 | 74548-9 | Reporter phone number | Reporter phone number | Tele | Pt | ^Event | Nom | SURVEY.AHRQ | 4 | ACTIVE | 2.48 | |||
2.48 | 74547-1 | Reporter email | Reporter email | EmailAddr | Pt | ^Event | Nom | SURVEY.AHRQ | 4 | ACTIVE | 2.48 | |||
2.21 | 48766-0 | Information source | Information source | Type | Pt | {system} | Nom | DOC.MISC | 2 | Source of info | ACTIVE | 2.73 | ||
2.07 | 32418-6 | Obstetric trimester Stated | Obstetric trimester | Time | Pt | ^Patient | Ord | Stated | H&P.HX | 2 | OB trimester Stated | ACTIVE | 2.27 | |
2.09 | 32624-9 | Race | Race | Type | Pt | ^Patient | Nom | CLIN | 2 | Race | ACTIVE | 2.73 |
COVID and telehealth documents
VersionFirstReleased | LOINC_NUM | Long Common Name | Component | Property | Time_Aspct | System | Scale_Typ | Method_Typ | Class | ClassType | Shortname | External_Copyright_Notice | Status | VersionLastChanged |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.69 | 95520-3 | Integrative medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Integrative medicine | DOC.ONTOLOGY | 2 | Integrative medicine Telehealth Note | ACTIVE | 2.69 | |
2.50 | 75496-0 | Telehealth Note | Note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth Note | ACTIVE | 2.54 | |
2.50 | 75497-8 | Telehealth Progress note | Progress note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth Prog note | ACTIVE | 2.73 | |
2.50 | 75498-6 | Telehealth Summary note | Summary note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth Summary note | ACTIVE | 2.54 | |
2.58 | 84009-0 | Spinal cord injury medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Spinal cord injury medicine | DOC.ONTOLOGY | 2 | SCIM Telehealth Note | ACTIVE | 2.58 | |
2.58 | 84069-4 | Multi-specialty program Telehealth Summary note | Summary note | Find | Pt | Telehealth | Doc | Multi-specialty program | DOC.ONTOLOGY | 2 | Multi-spec prog Telehealth Summary note | ACTIVE | 2.58 | |
2.58 | 84070-2 | Multi-specialty program Telehealth Plan of care note | Plan of care note | Find | Pt | Telehealth | Doc | Multi-specialty program | DOC.ONTOLOGY | 2 | Mult-spec prg Telehlth Plan of care note | ACTIVE | 2.58 | |
2.58 | 84215-3 | Mental health Telehealth Note | Note | Find | Pt | Telehealth | Doc | Mental health | DOC.ONTOLOGY | 2 | Mental health Telehealth Note | ACTIVE | 2.58 | |
2.58 | 84231-0 | Neurology Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Neurology | DOC.ONTOLOGY | 2 | Neurology Telehealth Consult note | ACTIVE | 2.58 | |
2.58 | 84232-8 | Neurology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Neurology | DOC.ONTOLOGY | 2 | Neurology Telehealth Note | ACTIVE | 2.58 | |
2.58 | 84233-6 | Neurology Telehealth Initial evaluation note | Initial evaluation note | Find | Pt | Telehealth | Doc | Neurology | DOC.ONTOLOGY | 2 | Neurology Telehealth Initial eval note | ACTIVE | 2.58 | |
2.58 | 84274-0 | Nurse Telehealth Note | Note | Find | Pt | Telehealth | Doc | Nurse | DOC.ONTOLOGY | 2 | Nurse Telehealth Note | ACTIVE | 2.58 | |
2.58 | 85206-1 | Telehealth Initial evaluation note | Initial evaluation note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth Initial eval note | ACTIVE | 2.58 | |
2.58 | 85207-9 | Telehealth Education note | Education note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth Educ note | ACTIVE | 2.58 | |
2.58 | 85208-7 | Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth Consult note | ACTIVE | 2.58 | |
2.61 | 85888-6 | Multi-specialty program Telehealth Note | Note | Find | Pt | Telehealth | Doc | Multi-specialty program | DOC.ONTOLOGY | 2 | Multi-spec prog Telehealth Note | ACTIVE | 2.61 | |
2.61 | 86208-6 | Cardiology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Cardiovascular disease | DOC.ONTOLOGY | 2 | Cardiology Telehealth Note | ACTIVE | 2.61 | |
2.64 | 89031-9 | Hematology Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Hematology | DOC.ONTOLOGY | 2 | Hematology Telehealth Consult note | ACTIVE | 2.64 | |
2.64 | 89032-7 | Nephrology Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Nephrology | DOC.ONTOLOGY | 2 | Nephrology Telehealth Consult note | ACTIVE | 2.64 | |
2.64 | 89033-5 | Urology Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Urology | DOC.ONTOLOGY | 2 | Urology Telehealth Consult note | ACTIVE | 2.64 | |
2.65 | 89883-3 | Emergency medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Emergency medicine | DOC.ONTOLOGY | 2 | Emergency med Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89884-1 | Hematology+Medical oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Hematology+Medical oncology | DOC.ONTOLOGY | 2 | HemOnc Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89885-8 | Pain medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pain medicine | DOC.ONTOLOGY | 2 | Pain medicine Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89886-6 | Palliative care Telehealth Note | Note | Find | Pt | Telehealth | Doc | Palliative care | DOC.ONTOLOGY | 2 | Palliative care Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89887-4 | Adolescent medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Adolescent medicine | DOC.ONTOLOGY | 2 | Adolescent med Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89888-2 | Pediatrics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pediatrics | DOC.ONTOLOGY | 2 | Peds Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89889-0 | Physical medicine and rehab Telehealth Note | Note | Find | Pt | Telehealth | Doc | Physical medicine and rehab | DOC.ONTOLOGY | 2 | PM+R Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89890-8 | Diabetology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Diabetology | DOC.ONTOLOGY | 2 | Diabetology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89891-6 | Endocrinology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Endocrinology | DOC.ONTOLOGY | 2 | Endocrinology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89892-4 | Infectious disease Telehealth Note | Note | Find | Pt | Telehealth | Doc | Infectious disease | DOC.ONTOLOGY | 2 | Infectious disease Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89893-2 | Clinical genetics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Clinical genetics | DOC.ONTOLOGY | 2 | Clinical genetics Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89894-0 | Neonatal perinatal medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Neonatal perinatal medicine | DOC.ONTOLOGY | 2 | Neo peri med Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89895-7 | Allergy and Immunology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Allergy+Immunology | DOC.ONTOLOGY | 2 | Allergy+Immunology Telehealth Note | ACTIVE | 2.66 | |
2.65 | 89896-5 | Developmental-behavioral pediatrics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Developmental-behavioral pediatrics | DOC.ONTOLOGY | 2 | Develop-behav peds Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89897-3 | Gynecology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Gynecology | DOC.ONTOLOGY | 2 | Gynecology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89898-1 | Nephrology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Nephrology | DOC.ONTOLOGY | 2 | Nephrology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89899-9 | Orthopaedic surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Orthopaedic surgery | DOC.ONTOLOGY | 2 | Orthopaedic surgery Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89900-5 | Rheumatology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Rheumatology | DOC.ONTOLOGY | 2 | Rheumatology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89901-3 | Sports medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Sports medicine | DOC.ONTOLOGY | 2 | Sports medicine Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89902-1 | Otolaryngology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Otolaryngology | DOC.ONTOLOGY | 2 | Otolaryngology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 89903-9 | Urology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Urology | DOC.ONTOLOGY | 2 | Urology Telehealth Note | ACTIVE | 2.65 | |
2.65 | 90008-4 | Pharmacogenomics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pharmacogenomics | DOC.ONTOLOGY | 2 | Pharmacogenomics Telehealth Note | ACTIVE | 2.65 | |
2.65 | 90712-1 | Sleep medicine Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Sleep medicine | DOC.ONTOLOGY | 2 | Sleep med Telehealth Consult note | ACTIVE | 2.65 | |
2.68 | 94821-6 | COVID-19 Intubation advance directives | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Intubation Adv Dir | ACTIVE | 2.70 | |
2.68 | 95407-3 | Cardiopulmonary Telehealth Note | Note | Find | Pt | Telehealth | Doc | Cardiovascular disease+Pulmonary disease | DOC.ONTOLOGY | 2 | Cardio+Pulm dis Telehealth Note | ACTIVE | 2.78 | |
2.68 | 95412-3 | COVID-19 case report | COVID-19 case report | Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Case rprt | ACTIVE | 2.70 | |
2.68 | 95381-0 | Telephone encounter COVID-19 note | COVID-19 note | Find | Pt | Telephone encounter | Doc | {Role} | DOC.ONTOLOGY | 2 | Phone COVID-19 note | ACTIVE | 2.70 | |
2.69 | 95804-1 | Breastfeeding Telehealth Note | Note | Find | Pt | Telehealth | Doc | Breastfeeding | DOC.ONTOLOGY | 2 | Breastfeeding Telehealth Note | ACTIVE | 2.69 | |
2.65 | 90713-9 | Sleep medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Sleep medicine | DOC.ONTOLOGY | 2 | Sleep med Telehealth Note | ACTIVE | 2.65 | |
2.65 | 90714-7 | Pain medicine Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Pain medicine | DOC.ONTOLOGY | 2 | Pain medicine Telehealth Consult note | ACTIVE | 2.65 | |
2.65 | 90715-4 | Palliative care Telehealth Consult note | Consultation note | Find | Pt | Telehealth | Doc | Palliative care | DOC.ONTOLOGY | 2 | Palliative care Telehealth Consult note | ACTIVE | 2.65 | |
2.65 | 90716-2 | Psychiatry Telehealth Note | Note | Find | Pt | Telehealth | Doc | Psychiatry | DOC.ONTOLOGY | 2 | Psychiatric Telehealth Note | ACTIVE | 2.65 | |
2.66 | 91531-4 | Social worker Telehealth Note | Note | Find | Pt | Telehealth | Doc | Social worker | DOC.ONTOLOGY | 2 | SW Telehealth Note | ACTIVE | 2.66 | |
2.66 | 92913-3 | Immunology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Immunology | DOC.ONTOLOGY | 2 | Immunology Telehealth Note | ACTIVE | 2.66 | |
2.68 | 94594-9 | Neurological surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Neurological surgery | DOC.ONTOLOGY | 2 | Neuro surgery Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94595-6 | Pharmacology Telehealth Medication management note | Medication management note | Find | Pt | Telehealth | Doc | Pharmacology | DOC.ONTOLOGY | 2 | Pharmacology Telehealth Med mgmt note | ACTIVE | 2.68 | |
2.68 | 94721-8 | COVID-19 Evaluation note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Eval note | ACTIVE | 2.70 | |
2.68 | 94722-6 | COVID-19 Initial Evaluation form | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Initial Eval form | ACTIVE | 2.70 | |
2.68 | 94723-4 | Emergency department COVID-19 Initial Evaluation form | COVID-19+ |
Find | Pt | Emergency department | Doc | {Role} | DOC.ONTOLOGY | 2 | ED COVID-19 Initial Eval form | ACTIVE | 2.70 | |
2.68 | 94724-2 | Pulmonary Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pulmonary disease | DOC.ONTOLOGY | 2 | Pulmonary disease Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94725-9 | Aerodigestive medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Aerodigestive medicine | DOC.ONTOLOGY | 2 | Aerodigestive med Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94726-7 | Cleft and Craniofacial Telehealth Note | Note | Find | Pt | Telehealth | Doc | Cleft and Craniofacial | DOC.ONTOLOGY | 2 | Cleft+Craniofacial Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94770-5 | Wound, Ostomy, and Continence Care Telehealth Note | Note | Find | Pt | Telehealth | Doc | Wound, ostomy, and continence care | DOC.ONTOLOGY | 2 | WOC Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94771-3 | Anesthesiology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Anesthesiology | DOC.ONTOLOGY | 2 | Anesthesiology Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94772-1 | Blood banking and transfusion medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Blood banking and transfusion medicine | DOC.ONTOLOGY | 2 | Bld Bnk+Trans Med Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94773-9 | Burn management Telehealth Note | Note | Find | Pt | Telehealth | Doc | Burn management | DOC.ONTOLOGY | 2 | Burn Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94774-7 | Cardiac surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Cardiac surgery | DOC.ONTOLOGY | 2 | Cardiac surgery Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94775-4 | Critical care medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Critical Care Medicine | DOC.ONTOLOGY | 2 | CCM Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94776-2 | Dentistry Telehealth Note | Note | Find | Pt | Telehealth | Doc | Dentistry | DOC.ONTOLOGY | 2 | Dentistry Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94777-0 | Dermatology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Dermatology | DOC.ONTOLOGY | 2 | Dermatology Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94778-8 | Ethics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Ethics | DOC.ONTOLOGY | 2 | Ethics Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94779-6 | Family medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Family medicine | DOC.ONTOLOGY | 2 | Fam Med Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94780-4 | Gastroenterology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Gastroenterology | DOC.ONTOLOGY | 2 | Gastroenterology Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94781-2 | General medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | General medicine | DOC.ONTOLOGY | 2 | General medicine Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94782-0 | Surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Surgery | DOC.ONTOLOGY | 2 | Surgery Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94783-8 | Geriatric medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Geriatric medicine | DOC.ONTOLOGY | 2 | Geri med Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94784-6 | Gynecologic oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Gynecologic oncology | DOC.ONTOLOGY | 2 | Gyn Onc Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94785-3 | Healthcare navigator Telehealth Note | Note | Find | Pt | Telehealth | Doc | Healthcare navigator | DOC.ONTOLOGY | 2 | Navigator Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94786-1 | Hematology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Hematology | DOC.ONTOLOGY | 2 | Hematology Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94787-9 | Interventional radiology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Interventional radiology | DOC.ONTOLOGY | 2 | IR Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94788-7 | Clinical pathology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Clinical pathology | DOC.ONTOLOGY | 2 | Clin Path Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94789-5 | Maternal and fetal medicine Telehealth Note | Note | Find | Pt | Telehealth | Doc | Maternal and fetal medicine | DOC.ONTOLOGY | 2 | Mat fetal med Telehealth Note | ACTIVE | 2.73 | |
2.68 | 94790-3 | Nutrition and dietetics Telehealth Note | Note | Find | Pt | Telehealth | Doc | Nutrition and dietetics | DOC.ONTOLOGY | 2 | Nutr+diet Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94791-1 | Occupational therapy Telehealth Note | Note | Find | Pt | Telehealth | Doc | Occupational therapy | DOC.ONTOLOGY | 2 | OT Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94792-9 | Oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Oncology | DOC.ONTOLOGY | 2 | Oncology Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94793-7 | Wound care management Telehealth Note | Note | Find | Pt | Telehealth | Doc | Wound care management | DOC.ONTOLOGY | 2 | Wound care management Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94794-5 | Ophthalmology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Ophthalmology | DOC.ONTOLOGY | 2 | Ophthalmol Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94795-2 | Pastoral care Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pastoral care | DOC.ONTOLOGY | 2 | Pastoral Care Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94796-0 | Pharmacology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Pharmacology | DOC.ONTOLOGY | 2 | Pharmacology Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94797-8 | Plastic surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Plastic surgery | DOC.ONTOLOGY | 2 | Plastic surgery Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94798-6 | Psychology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Psychology | DOC.ONTOLOGY | 2 | Psych Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94799-4 | Radiation oncology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Radiation oncology | DOC.ONTOLOGY | 2 | Radiation Onc Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94800-0 | Rapid response team Telehealth Note | Note | Find | Pt | Telehealth | Doc | Rapid response team | DOC.ONTOLOGY | 2 | Rapid response team Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94801-8 | Recreational therapy Telehealth Note | Note | Find | Pt | Telehealth | Doc | Recreational therapy | DOC.ONTOLOGY | 2 | Rec therapy Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94802-6 | Respiratory therapy Telehealth Note | Note | Find | Pt | Telehealth | Doc | Respiratory therapy | DOC.ONTOLOGY | 2 | Resp therapy Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94803-4 | Speech-language pathology Telehealth Note | Note | Find | Pt | Telehealth | Doc | Speech-language pathology | DOC.ONTOLOGY | 2 | Speech-lang path Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94804-2 | Trauma Telehealth Note | Note | Find | Pt | Telehealth | Doc | Trauma | DOC.ONTOLOGY | 2 | Trauma Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94805-9 | Vascular surgery Telehealth Note | Note | Find | Pt | Telehealth | Doc | Vascular surgery | DOC.ONTOLOGY | 2 | Vascular surgery Telehealth Note | ACTIVE | 2.68 | |
2.68 | 94806-7 | COVID-19 Intubation Consultation note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Intub+Consult | ACTIVE | 2.70 | |
2.68 | 94807-5 | Attending COVID-19 Intubation Consultation note | COVID-19+ |
Find | Pt | {Setting} | Doc | Attending | DOC.ONTOLOGY | 2 | Attend COVID-19 Intub+Consult | ACTIVE | 2.70 | |
2.68 | 94808-3 | Resident COVID-19 Intubation Consultation note | COVID-19+ |
Find | Pt | {Setting} | Doc | Resident | DOC.ONTOLOGY | 2 | Res COVID-19 Intub+Consult | ACTIVE | 2.70 | |
2.68 | 94809-1 | COVID-19 Intubation Progress note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Intub+Progress | ACTIVE | 2.70 | |
2.68 | 94810-9 | COVID-19 Intubation Procedure note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Intub Proced | ACTIVE | 2.70 | |
2.68 | 94811-7 | COVID-19 Intubation Evaluation note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Intub Eval note | ACTIVE | 2.70 | |
2.68 | 94812-5 | COVID-19 Intubation and Cardiopulmonary resuscitation note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Intub+CPR | ACTIVE | 2.70 | |
2.68 | 94813-3 | Team COVID-19 Intubation Conference note | COVID-19+ |
Find | Pt | {Setting} | Doc | Team | DOC.ONTOLOGY | 2 | Team COVID-19 Intub Conference | ACTIVE | 2.70 | |
2.68 | 94814-1 | Critical care medicine COVID-19 Consultation note | COVID-19+ |
Find | Pt | {Setting} | Doc | Critical Care Medicine | DOC.ONTOLOGY | 2 | CCM COVID-19 Consult note | ACTIVE | 2.70 | |
2.73 | 100282-3 | Vaccine exemption certificate | Vaccine exemption certificate | Find | Pt | {Setting} | Doc | {Role} | DOC.ADMIN | 2 | Vaccine exemption cert | ACTIVE | 2.73 | |
2.73 | 100458-9 | Outpatient COVID-19 Intubation Progress note | COVID-19+ |
Find | Pt | Outpatient | Doc | DOC.ONTOLOGY | 2 | OP COVID-19 Intub+Progress | ACTIVE | 2.73 | ||
2.73 | 100459-7 | Outpatient COVID-19 Progress note | COVID-19+ |
Find | Pt | Outpatient | Doc | {Role} | DOC.ONTOLOGY | 2 | OP COVID-19 Progress note | ACTIVE | 2.73 | |
2.73 | 100651-9 | Hospital COVID-19 Intubation Progress note | COVID-19+ |
Find | Pt | Hospital | Doc | {Role} | DOC.ONTOLOGY | 2 | Hosp COVID-19 Intub+Progress | ACTIVE | 2.73 | |
2.73 | 100658-4 | Hospital COVID-19 Progress note | COVID-19+ |
Find | Pt | Hospital | Doc | DOC.ONTOLOGY | 2 | Hosp COVID-19 Progress note | ACTIVE | 2.73 | ||
2.70 | 96874-3 | COVID-19 Immunization note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Immunization note | ACTIVE | 2.70 | |
2.70 | 97499-8 | Proof of COVID-19 recovery certificate | Proof of COVID-19 recovery certificate | Find | Pt | {Setting} | Doc | {Role} | DOC.ADMIN | 2 | Proof of COVID-19 recovery Cert | ACTIVE | 2.70 | |
2.70 | 97500-3 | Proof of COVID-19 immunization or negative status certificate | Proof of COVID-19 immunization or negative status certificate | Find | Pt | {Setting} | Doc | {Role} | DOC.ADMIN | 2 | COVID-19 Immunization or Neg Cert | ACTIVE | 2.70 | |
2.70 | 96736-4 | COVID-19 Procedure note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Proced note | ACTIVE | 2.70 | |
2.70 | 96737-2 | COVID-19 Consultation note | COVID-19+ |
Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 Consult note | ACTIVE | 2.70 | |
2.70 | 96738-0 | COVID-19 letter | COVID-19 letter | Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 letter | ACTIVE | 2.70 | |
2.70 | 96739-8 | Telehealth COVID-19 note | COVID-19 note | Find | Pt | Telehealth | Doc | {Role} | DOC.ONTOLOGY | 2 | Telehealth COVID-19 note | ACTIVE | 2.70 | |
2.70 | 96740-6 | COVID-19 note | COVID-19 note | Find | Pt | {Setting} | Doc | {Role} | DOC.ONTOLOGY | 2 | COVID-19 note | ACTIVE | 2.70 |
COVID-19 Survey terms
VersionFirstReleased | LOINC_NUM | Long Common Name | Component | Property | Time_Aspct | System | Scale_Typ | Method_Typ | Class | ClassType | Shortname | External_Copyright_Notice | Status | VersionLastChanged |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2.71 | 98168-8 | How often do you keep a distance of at least 2 meters from others | How often do you keep a distance of at least 2 meters from others | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98169-6 | Stay at home to avoid social contact | Stay at home to avoid social contact | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98170-4 | Wear face mask in public | Wear face mask in public | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98171-2 | Has been offered COVID-19 vaccine | Has been offered COVID-19 vaccine | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98172-0 | Accepted or will accept COVID-19 vaccination once offered | Accepted or will accept COVID-19 vaccination once offered | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96831-3 | Coronavirus racial bias scale [CRBS] | Coronavirus racial bias scale | - | Pt | ^Patient | - | CRBS | PANEL.SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96875-0 | I believe the country has become more dangerous for people in my racial/ethnic group because of fear of the coronavirus [CRBS] | I believe the country has become more dangerous for people in my racial or ethnic group because of fear of the coronavirus | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96887-5 | Thinking about your current social habits, in the last 5 days: I have gone on shopping trips or outings that were just for fun | Gone on shopping trips or outings that were just for fun | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96888-3 | Thinking about your current social habits, in the last 5 days: I have visited nursing homes or long-term care facilities (outside of work duties) | Visited nursing homes or long-term care facilities (outside of work duties) | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98071-4 | Post COVID-19 functional status scale [PCFS] | Post COVID-19 functional status scale | - | Pt | ^Patient | - | PCFS | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.71 | 98072-2 | Post COVID-19 functional status grade [PCFS] | Post COVID-19 functional status grade | Find | Pt | ^Patient | Ord | PCFS | SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.71 | 98162-1 | Financial problems since the beginning of the pandemic | Financial problems since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98160-5 | Treatment sessions cancelled by doctor or patient since the beginning of the pandemic | Treatment sessions cancelled by doctor or patient since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98159-7 | Treatment sessions postponed by doctor or patient since the beginning of the pandemic | Treatment sessions postponed by doctor or patient since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98158-9 | Problems accessing medication since the beginning of the pandemic | Problems accessing medication since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98157-1 | Routine doctor's visits AndOr check-ups postponed since the beginning of the pandemic | Routine doctor's visits &or check-ups postponed since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98156-3 | Routine doctor's visits AndOr check-ups cancelled since the beginning of the pandemic | Routine doctor's visits &or check-ups cancelled since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98154-8 | SARS-CoV-2-related socioeconomic questionnaire for adults | SARS-CoV-2-related socioeconomic questionnaire for adults | - | Pt | ^Patient | - | PANEL.SURVEY.COVID | 4 | © 2021 E. Sicuri, I. Lopes, E. Tacconelli, M. Giannella. Used with permission. | ACTIVE | 2.72 | ||
2.71 | 98180-3 | Received any financial or material aid in last 12 months | Received any financial or material aid in last 12 Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98179-5 | Financial problems in last 12 months | Financial problems in last 12 Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98178-7 | Treatment sessions cancelled by doctor or patient in the last 12 months | Treatment sessions cancelled by doctor or patient in the last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98177-9 | Treatment sessions postponed by doctor or patient in the last 12 months | Treatment sessions postponed by doctor or patient in the last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98176-1 | Problems accessing medication in last 12 months | Problems accessing medication in last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98175-3 | Routine doctor's visits AndOr check-ups postponed in the last 12 months | Routine doctor's visits &or check-ups postponed in the last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98174-6 | Routine doctor's visits AndOr check-ups cancelled in the last 12 months | Routine doctor's visits &or check-ups cancelled in the last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98173-8 | Reasons for not accepting COVID-19 vaccine | Reasons for not accepting COVID-19 vaccine | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98167-0 | How often do you wash your hands with hand-soap or hydro-alcoholic solutions | How often do you wash your hands with hand-soap or hydro-alcoholic solutions | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98166-2 | What do you think is your current risk that, in case of infection or re-infection, you will experience severe complications or even death | What do you think is your current risk that, in case of infection or re-infection, you will experience severe complications or even death | Score | Pt | ^Patient | Qn | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98165-4 | What do you think is your current risk of infection or re-infection | What do you think is your current risk of infection or re-infection | Score | Pt | ^Patient | Qn | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98164-7 | How often have you recently looked for information on COVID-19 | How often have you recently looked for information on COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.71 | 98163-9 | Received any financial or material aid since the beginning of the pandemic | Received any financial or material aid since the beginning of the pandemic | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.72 | 98953-3 | Able to participate in remote learning in last 12 months | Able to participate in remote learning in last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98952-5 | Reason for not participating in remote learning in last 12 months | Reason for not participating in remote learning in last 12Mo | Find | 12Mo | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98951-7 | Amount of school lost in last 12 months | Amount of school lost in last 12Mo | Time | 12Mo | ^Patient | Qn | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98950-9 | How long were classes suspended in last 12 months | How long were classes suspended in last 12Mo | Time | 12Mo | ^Patient | Qn | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98949-1 | Were classes suspended in last 12 months | Were classes suspended in last 12Mo | Find | 12Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98948-3 | SARS-CoV-2-related socioeconomic questionnaire for school-age children 12 month follow-up | SARS-CoV-2-related socioeconomic questionnaire for school-age children 12Mo follow-up | - | 12Mo | ^Patient | - | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98947-5 | SARS-CoV-2-related socioeconomic questionnaire for school-age children intake questions | SARS-CoV-2-related socioeconomic questionnaire for school-age children intake questions | - | Pt | ^Patient | - | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98901-2 | Received or applied for temporary assistance since the beginning of the pandemic | Received or applied for temporary assistance since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98896-4 | Household income changed significantly since the beginning of the pandemic | Household income changed significantly since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98895-6 | Level of worry that household income has been or will be negatively impacted by COVID-19 | Level of worry that household income has been or will be negatively impacted by COVID-19 | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98894-9 | Level of worry that asset value has been or will be negatively impacted by COVID-19 | Level of worry that asset value has been or will be negatively impacted by COVID-19 | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98893-1 | Difficulty level of paying expenses in past month | Difficulty level of paying expenses in past Mo | Find | 1Mo | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98892-3 | Emergency expense payment method | Emergency expense payment method | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98891-5 | Methods using or plan to use to cover expenses | Methods using or plan to use to cover expenses | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98890-7 | Received or applied for unemployment insurance since the beginning of the pandemic | Received or applied for unemployment insurance since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98889-9 | COVID-19 related household finances | COVID-19 related household finances | - | Pt | ^Patient | - | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.70 | 97147-3 | COVID-19 experiences - coping panel [COVEX] | COVID-19 experiences - coping panel | - | Pt | ^Patient | - | COVEX | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.70 | 97146-5 | How helpful was your child's coping strategy during the COVID-19 outbreak | How helpful was your child's coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97145-7 | Helpful coping strategy your child used during the COVID-19 outbreak | Helpful coping strategy your child used during the COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97144-0 | How helpful has virtual entertainment been as a coping strategy to your child during the COVID-19 outbreak | How helpful has virtual entertainment been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97143-2 | How helpful has playing online games been as a coping strategy to your child during the COVID-19 outbreak | How helpful has playing online games been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97142-4 | How helpful has playing board games, cards with family members been as a coping strategy to your child during the COVID-19 outbreak | How helpful has playing board games, cards with family members been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97141-6 | How helpful have arts and crafts projects been as a coping strategy to your child during the COVID-19 outbreak | How helpful have arts and crafts projects been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97140-8 | How helpful has cooking or baking been as a coping strategy to your child during the COVID-19 outbreak | How helpful has cooking or baking been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97139-0 | How helpful has exercising or walking been as a coping strategy to your child during the COVID-19 outbreak | How helpful has exercising or walking been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97138-2 | How helpful has talking to a therapist been as a coping strategy to your child during the COVID-19 outbreak | How helpful has talking to a therapist been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97137-4 | How helpful has virtual learning or school been as a coping strategy to your child during the COVID-19 outbreak | How helpful has virtual learning or school been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97136-6 | How helpful has texting, calling or video-calling family members or friends been as a coping strategy to your child during the COVID-19 outbreak | How helpful has texting, calling or video-calling family members or friends been as a coping strategy to your child during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97123-4 | COVID-19 experiences - employment and school changes panel [COVEX] | COVID-19 experiences - employment and school changes panel | - | Pt | ^Patient | - | COVEX | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.70 | 97122-6 | Household member who lost job or income due to COVID-19 outbreak | Person who lost job or income due to COVID-19 outbreak | Find | Pt | ^Household member | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97121-8 | Household job or income loss due to the COVID-19 outbreak | Household job or income loss due to the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97120-0 | Difficulty getting work or schoolwork done because of your home environment during the COIVD-19 outbreak | Difficulty getting work or schoolwork done because of your home environment during the COIVD-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97119-2 | Difficulty getting work or schoolwork done because of other responsibilities at home during the COVID-19 outbreak | Difficulty getting work or schoolwork done because of other responsibilities at home during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97118-4 | Increase or decrease in schoolwork during the COVID-19 outbreak | Increase or decrease in schoolwork during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97117-6 | School has offered classes remotely during the COVID-19 outbreak | School has offered classes remotely during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97116-8 | Student during the COVID-19 outbreak | Student during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97115-0 | Student in the few weeks before COVID-19 outbreak | Student in the few weeks before COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97114-3 | Work setting during the COVID-19 outbreak | Work setting during the COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97113-5 | Significant job changes during the COVID-19 outbreak | Significant job changes during the COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97109-3 | New employment during the COVID-19 outbreak | New employment during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97108-5 | Employment status in the 2 weeks prior to COVID-19 outbreak | Employment status in the 2W prior to COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97092-1 | How often medical or health websites used as source of information for COVID-19 | How often medical or health websites used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97091-3 | How often Federal Government used as source of information for COVID-19 | How often Federal Government used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97090-5 | How often local government officials used as source of information for COVID-19 | How often local government officials used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97089-7 | How often medical providers used as source of information for COVID-19 | How often medical providers used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97088-9 | How often friends, family or neighbors used as source of information for COVID-19 | How often friends, family or neighbors used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97087-1 | Effect of social media (e.g., TikTok, Reddit) as source of information on mental health | Effect of social media (e.g., TikTok, Reddit) as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97086-3 | Effect of Twitter as source of information on mental health | Effect of Twitter as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97085-5 | Effect of Instagram or Snapchat as source of information on mental health | Effect of Instagram or Snapchat as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97084-8 | Effect of Facebook as source of information on mental health | Effect of Facebook as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97079-8 | Effect of local government officials as source of information on mental health | Effect of local government officials as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97078-0 | Effect of friends, family or neighbors as source of information on mental health | Effect of friends, family or neighbors as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97077-2 | Time spent per day getting information about COVID-19 and/or its impact | Time spent per day getting information about COVID-19 &or its impact | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97076-4 | Common news sources | Common news sources | Type | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97075-6 | Total score [CAS] | Total score | Score | Pt | ^Patient | Qn | CAS | SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.70 | 97074-9 | Mean score [CRBS] | Mean score | Score | Pt | ^Patient | Qn | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96892-5 | COVID-19 participant experience survey | COVID-19 participant experience survey | - | Pt | ^Patient | - | COPE | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.70 | 96891-7 | How often in the past month are you doing the recommended pandemic hygiene | How often in the past Mo are you doing the recommended pandemic hygiene | Find | 1Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96890-9 | Frequency of social interaction with people outside my home | Frequency of social interaction with people outside my home | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96889-1 | Close contact with someone who is in a risk group for COVID-19 | Close contact with someone who is in a risk group for COVID-19 | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96886-7 | Thinking about your current social habits, in the last 5 days: I have attended social gatherings outside my home of less than 10 people | Attended social gatherings outside my home of less than 10 people | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96885-9 | Thinking about your current social habits, in the last 5 days: I have attended social gatherings outside my home of more than 10 people | Attended social gatherings outside my home of more than 10 people | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96884-2 | Went to workplace or volunteer site outside home | Went to workplace or volunteer site outside home | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96883-4 | Stayed home all day | Stayed home all day | Find | 5D | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96882-6 | In the past month, have recommendations for socially distancing caused stress for you | In the past Mo, have recommendations for socially distancing caused stress for you | Find | 1Mo | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.77 | |||
2.70 | 96879-2 | People of my race/ethnicity are more likely to get the coronavirus [CRBS] | People of my race or ethnicity are more likely to get the coronavirus | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96878-4 | Most social and mass media reports about the coronavirus create bias against people of my racial/ethnic group [CRBS] | Most social and mass media reports about the coronavirus create bias against people of my racial or ethnic group | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96839-6 | Nauseous or had stomach problems when I thought about or was exposed to information about the coronavirus in past 2 weeks | Nauseous or had stomach problems when I thought about or was exposed to information about the coronavirus in past 2W | Find | 2W | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96838-8 | Lost interest in eating when I thought about or was exposed to information about the coronavirus in past 2 weeks | Lost interest in eating when I thought about or was exposed to information about the coronavirus in past 2W | Find | 2W | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96837-0 | Paralyzed or frozen when I thought about or was exposed to information about the coronavirus in past 2 weeks | Paralyzed or frozen when I thought about or was exposed to information about the coronavirus in past 2W | Find | 2W | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96836-2 | Trouble falling or staying asleep due to thinking about the coronavirus in past 2 weeks | Trouble falling or staying asleep due to thinking about the coronavirus in past 2W | Find | 2W | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96835-4 | Dizzy, lightheaded, or faint, when exposed to news about the coronavirus in past 2 weeks | Dizzy, lightheaded, or faint, when exposed to news about the coronavirus in past 2W | Find | 2W | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96834-7 | Coronavirus anxiety scale | Coronavirus anxiety scale | - | 2W | ^Patient | - | CAS | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.70 | 96833-9 | Since the coronavirus I have seen a lot more cyberbullying of people of my race/ethnicity [CRBS] | Since the coronavirus I have seen a lot more cyberbullying of people of my race or ethnicity | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96832-1 | Due to the coronavirus I have been cyberbullied because of my race/ethnicity [CRBS] | Due to the coronavirus I have been cyberbullied because of my race or ethnicity | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 97073-1 | Received COVID-19 vaccine | Received COVID-19 vaccine | Find | Pt | ^Patient | Ord | VACCIN | 2 | Rcvd COVID-19 vaccine | ACTIVE | 2.70 | ||
2.70 | 97067-3 | Allergic reaction to first COVID-19 vaccine dose | Allergic reaction to first COVID-19 vaccine dose | Find | Pt | ^Patient | Ord | VACCIN | 2 | Aller react 1st COVID-19 dose | ACTIVE | 2.70 | ||
2.70 | 97065-7 | Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine | Medical history for preventive vaccination against COVID-19 (Coronavirus Disease 2019) - with mRNA vaccine | - | Pt | ^Patient | - | PANEL.VACCIN | 2 | Hx for COVID -19 vaccine | ACTIVE | 2.70 | ||
2.72 | 98888-1 | Received or applied for nutrition assistance since the beginning of the pandemic | Received or applied for nutrition assistance since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98887-3 | Received or applied for social security since the beginning of the pandemic | Received or applied for social security since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98886-5 | Received or applied for supplemental social security since the beginning of the pandemic | Received or applied for supplemental social security since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98885-7 | Received or applied for government health insurance since the beginning of the pandemic | Received or applied for government health insurance since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98884-0 | Received or applied for paycheck protection since the beginning of the pandemic | Received or applied for paycheck protection since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98883-2 | Received or applied for other government aid since the beginning of the pandemic | Received or applied for other government aid since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98882-4 | Received or applied for assistance from a union since the beginning of the pandemic | Received or applied for assistance from a union since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98881-6 | Received or applied for assistance from a religious organization since the beginning of the pandemic | Received or applied for assistance from a religious organization since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98880-8 | Received or applied for assistance from community organization since the beginning of the pandemic | Received or applied for assistance from community organization since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98879-0 | Received or applied for assistance from a food pantry since the beginning of the pandemic | Received or applied for assistance from a food pantry since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98878-2 | Received or applied for other assistance since the beginning of the pandemic | Received or applied for other assistance since the beginning of the pandemic | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98877-4 | Amount of school lost | Amount of school lost | Time | Pt | ^Patient | Qn | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98876-6 | Reason for not participating in remote learning | Reason for not participating in remote learning | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98875-8 | Able to participate in remote learning | Able to participate in remote learning | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98874-1 | How long were classes suspended | How long were classes suspended | Time | Pt | ^Patient | Qn | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98873-3 | Were classes suspended | Were classes suspended | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 98872-5 | SARS-CoV-2-related socioeconomic questionnaire for school-age children | SARS-CoV-2-related socioeconomic questionnaire for school-age children | - | Pt | ^Patient | - | PANEL.SURVEY.COVID | 4 | © 2021 E. Sicuri, I. Lopes, E. Tacconelli, M. Giannella. Used with permission. | ACTIVE | 2.72 | ||
2.72 | 98871-7 | COVID-19 comorbidity and healthcare questionnaire | COVID-19 comorbidity and healthcare questionnaire | - | Pt | ^Patient | - | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.70 | 97096-2 | COVID-19 experiences - media use panel [COVEX] | COVID-19 experiences - media use panel | - | Pt | ^Patient | - | COVEX | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.71 | ||
2.70 | 97095-4 | How often social media used as source of information for COVID-19 | How often social media used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97094-7 | How often TV or radio used as source of information for COVID-19 | How often TV or radio used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97093-9 | How often print or online news used as source of information for COVID-19 | How often print or online news used as source of information for COVID-19 | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97083-0 | Effect of radio or podcast as source of information on mental health | Effect of radio or podcast as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97082-2 | Effect of print or online news as source of information on mental health | Effect of print or online news as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97081-4 | Effect of national and international health officials as source of information on mental health | Effect of national and international health officials as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97080-6 | Effect of national government officials as source of information on mental health | Effect of national government officials as source of information on mental health | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 96881-8 | Negative social media posts against people of my race/ethnicity have increased because of the coronavirus [CRBS] | Negative social media posts against people of my race or ethnicity have increased because of the coronavirus | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96880-0 | People of my race/ethnicity will not receive coronavirus healthcare as good as the care received by other groups [CRBS] | People of my race or ethnicity will not receive coronavirus healthcare as good as the care received by other groups | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96877-6 | I worry about people thinking I have the coronavirus simply because of my race/ethnicity [CRBS] | I worry about people thinking I have the coronavirus simply because of my race or ethnicity | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.70 | 96876-8 | People of my race/ethnicity are more likely to lose their job because of the coronavirus [CRBS] | People of my race or ethnicity are more likely to lose their job because of the coronavirus | Find | Pt | ^Patient | Ord | CRBS | SURVEY.COVID | 4 | Copyright 2020 Fisher, Celia B. & Yip, Tiffany - Fordham University Center for Ethics Education. Used with permission. | ACTIVE | 2.71 | |
2.61 | 85658-3 | Occupation [Type] | Occupation | Type | Pt | ^Patient | Nom | ADMIN.PATIENT.DEMOG | 2 | Occupation Type | ACTIVE | 2.66 | ||
2.70 | 97135-8 | Impact of COVID-19 outbreak on life | Impact of COVID-19 outbreak on life | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97134-1 | How helpful was your coping strategy during the COVID-19 outbreak | How helpful was your coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97133-3 | Helpful coping strategy used during the COVID-19 outbreak | Helpful coping strategy used during the COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97132-5 | How helpful has virtual entertainment been as a coping strategy during the COVID-19 outbreak | How helpful has virtual entertainment been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97131-7 | How helpful has playing online games been as a coping strategy during the COVID-19 outbreak | How helpful has playing online games been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97126-7 | How helpful has exercising or walking been as a coping strategy during the COVID-19 outbreak | How helpful has exercising or walking been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97125-9 | How helpful has talking to a therapist been as a coping strategy during the COVID-19 outbreak | How helpful has talking to a therapist been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97124-2 | How helpful has texting, calling or video-calling family members or friends been as a coping strategy during the COVID-19 outbreak | How helpful has texting, calling or video-calling family members or friends been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97130-9 | How helpful has playing games with family members been as a coping strategy during the COVID-19 outbreak | How helpful has playing games with family members been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97129-1 | How helpful has cleaning or doing household chores been as a coping strategy during the COVID-19 outbreak | How helpful has cleaning or doing household chores been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97128-3 | How helpful have arts and crafts projects been as a coping strategy during the COVID-19 outbreak | How helpful have arts and crafts projects been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97127-5 | How helpful has cooking or baking been as a coping strategy during the COVID-19 outbreak | How helpful has cooking or baking been as a coping strategy during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97112-7 | Worked during the COVID-19 outbreak | Worked during the COVID-19 outbreak | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97111-9 | Job loss during the COVID-19 outbreak | Job loss during the COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.70 | 97110-1 | Work setting in the 2 weeks before the COVID-19 outbreak | Work setting in the 2W before the COVID-19 outbreak | Find | Pt | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.71 | |||
2.72 | 99357-6 | COVID-19 health questions panel | COVID-19 health questions panel | - | Pt | ^Patient | - | PANEL.SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 99351-9 | Informed of being at severe risk from COVID-19 due to an underlying health condition | Informed of being at severe risk from COVID-19 due to an underlying health condition | Find | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 99349-3 | Has or had COVID-19 | Has or had COVID-19 | Hx | Pt | ^Patient | Ord | SURVEY.COVID | 4 | ACTIVE | 2.72 | |||
2.72 | 99348-5 | Close contact with COVID-19 in last 2W | Close contact with COVID-19 in last 2W | Find | 2W | ^Patient | Nom | SURVEY.COVID | 4 | ACTIVE | 2.72 |